No., subject, TM-score, RMSD, Sequence Identity, Subject length, Aligned length, Description
1, d3wylA_, 1.0000, 0.00, 1.000, 315, 315, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF PDE10A COMPLEXED WITH 5- METHOXY-3-(1-PHENYL-1H-PYRAZOL-5-YL)-1-(3-(TRIFLUOROMETHYL)PHENYL) PYRIDAZIN-4(1H)-ONE
2, d5axqA_, 0.9976, 0.31, 1.000, 315, 315, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF PDE10A COMPLEXED WITH HIGHLY POTENT AND BRAIN-PENETRANT PDE10A INHIBITOR WITH 2-OXINDOLE SCAFFOLD
3, d5axpA_, 0.9975, 0.32, 1.000, 315, 315, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF PDE10A COMPLEXED WITH 1- (2-FLUORO-4-(2-OXO-13-OXAZOLIDIN-3-YL)PHENYL)-5-METHOXY-3-(1-PHENYL- 1H-PYRAZOL-5-YL)PYRIDAZIN-4(1H)-ONE
4, d5b4kA_, 0.9971, 0.35, 1.000, 315, 315, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN PDE10A COMPLEXED WITH N-(4-((5-METHYL-5H-PYRROLO[32-D]PYRIMIDIN-4-YL)OXY)PHENYL)-1H- BENZIMIDAZOL-2-AMINE
5, d3wykA_, 0.9971, 0.35, 1.000, 315, 315, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF PDE10A COMPLEXED WITH 3- (1-PHENYL-1H-PYRAZOL-5-YL)-1-(3-(TRIFLUOROMETHYL)PHENYL)PYRIDAZIN- 4(1H)-ONE
6, d5b4lA_, 0.9967, 0.37, 1.000, 315, 315, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN PDE10A COMPLEXED WITH 1-(CYCLOPROPYLMETHYL)-5-(2-(23-DIHYDRO-1H-IMIDAZO[12- A]BENZIMIDAZOL-1-YL)ETHOXY)-3-(1-PHENYL-1H-PYRAZOL-5-YL)PYRIDAZIN- 4(1H)-ONE
7, d5dh5B1, 0.9964, 0.39, 1.000, 321, 315, PDE10 COMPLEXED WITH N-[(1-METHYLPYRAZOL-4-YL)METHYL]-5-[[(1S2S)-2- (2-PYRIDYL)CYCLOPROPYL]METHOXY]PYRAZOLO[15-A]PYRIMIDIN-7-AMINE
8, d3wymA_, 0.9964, 0.39, 1.000, 315, 315, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF PDE10A COMPLEXED WITH 1- (2-FLUORO-4-(1H-PYRAZOL-1-YL)PHENYL)-5-METHOXY-3-(1-PHENYL-1H- PYRAZOL-5-YL)PYRIDAZIN-4(1H)-ONE
9, d3ui7B_, 0.9961, 0.41, 1.000, 315, 315, DISCOVERY OF ORALLY ACTIVE PYRAZOLOQUINOLINE AS A POTENT PDE10 INHIBITOR FOR THE MANAGEMENT OF SCHIZOPHRENIA
10, d4yqhB_, 0.9959, 0.42, 1.000, 321, 315, 2-[2-(4-PHENYL-1H-IMIDAZOL-2-YL)ETHYL]QUINOXALINE (SUNOVION COMPOUND 14) CO-CRYSTALLIZED WITH PDE10A
11, d4ajgD1, 0.9959, 0.41, 1.000, 321, 315, IDENTIFICATION AND STRUCTURAL CHARACTERIZATION OF PDE10 FRAGMENT INHIBITORS
12, d4ys7B_, 0.9957, 0.43, 1.000, 317, 315, CO-CRYSTAL STRUCTURE OF 2-[2-(58-DIMETHYL[124]TRIAZOLO[15- A]PYRAZIN-2-YL)ETHYL]-3-METHYL-3H-IMIDAZO[45-F]QUINOLINE (COMPOUND 39) WITH PDE10A
13, d5c2aA1, 0.9954, 0.44, 1.000, 321, 315, PDE10 COMPLEXED WITH 6-CHLORO-2-CYCLOPROPYL-N-[(24-DIMETHYLTHIAZOL-5- YL)METHYL]-5-METHYL-PYRIMIDIN-4-AMINE
14, d4zo5B1, 0.9954, 0.44, 1.000, 321, 315, PDE10 COMPLEXED WITH 4-ISOPROPOXY-2-(2-(3-(4-METHOXYPHENYL)-4-OXO-34- DIHYDROQUINAZOLIN-2-YL)ETHYL)ISOINDOLINE-13-DIONE
15, d3uuoB_, 0.9954, 0.44, 1.000, 315, 315, THE DISCOVERY OF POTENT SELECTIVITY AND ORALLY BIOAVAILABLE PYROZOLOQUINOLINES AS PDE10 INHIBITORS FOR THE TREATMENT OF SCHIZOPHRENIA
16, d4aelB1, 0.9953, 0.45, 1.000, 321, 315, PDE10A IN COMPLEX WITH THE INHIBITOR AZ5
17, p5xuiA_, 0.9952, 0.45, 1.000, 322, 315, CRYSTAL STRUCTURE OF PDE10A IN COMPLEX WITH 2-METHYL-5-[2-([12 4]TRIAZOLO[15-A]PYRIMIDIN-2-YL)ET HYL]PYRAZOLO[15-A]PYRIMIDIN-7-OL
18, d4ajdD1, 0.9952, 0.45, 1.000, 321, 315, IDENTIFICATION AND STRUCTURAL CHARACTERIZATION OF PDE10 FRAGMENT INHIBITORS
19, d4zo5A1, 0.9951, 0.46, 1.000, 321, 315, PDE10 COMPLEXED WITH 4-ISOPROPOXY-2-(2-(3-(4-METHOXYPHENYL)-4-OXO-34- DIHYDROQUINAZOLIN-2-YL)ETHYL)ISOINDOLINE-13-DIONE
20, d5c2eB1, 0.9950, 0.46, 1.000, 321, 315, PDE10 COMPLEXED WITH6-CHLORO-N-[(24-DIMETHYLTHIAZOL-5-YL)METHYL]-5- METHYL-2-[2-(2-PYRIDYL)ETHOXY]PYRIMIDIN-4-AMINE
21, d5c2aB1, 0.9950, 0.46, 1.000, 321, 315, PDE10 COMPLEXED WITH 6-CHLORO-2-CYCLOPROPYL-N-[(24-DIMETHYLTHIAZOL-5- YL)METHYL]-5-METHYL-PYRIMIDIN-4-AMINE
22, d5c2eA1, 0.9947, 0.48, 1.000, 321, 315, PDE10 COMPLEXED WITH6-CHLORO-N-[(24-DIMETHYLTHIAZOL-5-YL)METHYL]-5- METHYL-2-[2-(2-PYRIDYL)ETHOXY]PYRIMIDIN-4-AMINE
23, d5axpB_, 0.9947, 0.47, 1.000, 315, 315, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF PDE10A COMPLEXED WITH 1- (2-FLUORO-4-(2-OXO-13-OXAZOLIDIN-3-YL)PHENYL)-5-METHOXY-3-(1-PHENYL- 1H-PYRAZOL-5-YL)PYRIDAZIN-4(1H)-ONE
24, d4wn1A1, 0.9947, 0.48, 1.000, 322, 315, CRYSTAL STRUCTURE OF PDE10A IN COMPLEX WITH 1-METHYL-5-(1-METHYL-3- {[4-(QUINOLIN-2-YL)PHENOXY]METHYL}-1H-PYRAZOL-4-YL)PYRIDIN-2(1H)-ONE
25, d5dh4B1, 0.9946, 0.48, 1.000, 321, 315, PDE10 COMPLEXED WITH 5-CHLORO-N-[(24-DIMETHYLTHIAZOL-5-YL) METHYL]PYRAZOLO[15-A]PYRIMIDIN-7-AMINE
26, d3ws9A1, 0.9946, 0.48, 1.000, 322, 315, CRYSTAL STRUCTURE OF PDE10A IN COMPLEX WITH A BENZIMDAZOLE INHIBITOR
27, d4yqhA_, 0.9943, 0.49, 1.000, 321, 315, 2-[2-(4-PHENYL-1H-IMIDAZOL-2-YL)ETHYL]QUINOXALINE (SUNOVION COMPOUND 14) CO-CRYSTALLIZED WITH PDE10A
28, d4ajdA1, 0.9943, 0.49, 1.000, 322, 315, IDENTIFICATION AND STRUCTURAL CHARACTERIZATION OF PDE10 FRAGMENT INHIBITORS
29, d5axqB_, 0.9942, 0.50, 1.000, 316, 315, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF PDE10A COMPLEXED WITH HIGHLY POTENT AND BRAIN-PENETRANT PDE10A INHIBITOR WITH 2-OXINDOLE SCAFFOLD
30, d5b4lB_, 0.9941, 0.50, 1.000, 316, 315, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN PDE10A COMPLEXED WITH 1-(CYCLOPROPYLMETHYL)-5-(2-(23-DIHYDRO-1H-IMIDAZO[12- A]BENZIMIDAZOL-1-YL)ETHOXY)-3-(1-PHENYL-1H-PYRAZOL-5-YL)PYRIDAZIN- 4(1H)-ONE
31, p5xuiB_, 0.9940, 0.50, 1.000, 322, 315, CRYSTAL STRUCTURE OF PDE10A IN COMPLEX WITH 2-METHYL-5-[2-([12 4]TRIAZOLO[15-A]PYRIMIDIN-2-YL)ET HYL]PYRAZOLO[15-A]PYRIMIDIN-7-OL
32, d3wykB_, 0.9940, 0.51, 1.000, 315, 315, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF PDE10A COMPLEXED WITH 3- (1-PHENYL-1H-PYRAZOL-5-YL)-1-(3-(TRIFLUOROMETHYL)PHENYL)PYRIDAZIN- 4(1H)-ONE
33, d5b4kB_, 0.9939, 0.51, 1.000, 316, 315, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN PDE10A COMPLEXED WITH N-(4-((5-METHYL-5H-PYRROLO[32-D]PYRIMIDIN-4-YL)OXY)PHENYL)-1H- BENZIMIDAZOL-2-AMINE
34, d3wi2B1, 0.9939, 0.51, 1.000, 322, 315, CRYSTAL STRUCTURE OF PDE10A IN COMPLEX WITH INHIBITOR
35, d4ys7A1, 0.9938, 0.52, 1.000, 321, 315, CO-CRYSTAL STRUCTURE OF 2-[2-(58-DIMETHYL[124]TRIAZOLO[15- A]PYRAZIN-2-YL)ETHYL]-3-METHYL-3H-IMIDAZO[45-F]QUINOLINE (COMPOUND 39) WITH PDE10A
36, d3wymB_, 0.9938, 0.52, 1.000, 315, 315, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF PDE10A COMPLEXED WITH 1- (2-FLUORO-4-(1H-PYRAZOL-1-YL)PHENYL)-5-METHOXY-3-(1-PHENYL-1H- PYRAZOL-5-YL)PYRIDAZIN-4(1H)-ONE
37, d3ws8A1, 0.9938, 0.52, 1.000, 322, 315, CRYSTAL STRUCTURE OF PDE10A IN COMPLEX WITH A BENZIMIDAZOLE INHIBITOR
38, d2y0jB_, 0.9936, 0.37, 1.000, 314, 314, TRIAZOLOQUINAZOLINES AS A NOVEL CLASS OF PHOSPHODIESTERASE 10A (PDE10A) INHIBITORS PART 2 LEAD-OPTIMISATION.
39, d4mscA1, 0.9935, 0.53, 1.000, 327, 315, CRYSTAL STRUCTURE OF PDE10A2 WITH FRAGMENT ZT1595 (2-[(QUINOLIN-7- YLOXY)METHYL]QUINOLINE)
40, d5uwfD1, 0.9934, 0.53, 1.000, 321, 315, CRYSTAL STRUCTURE OF HUMAN PDE10A IN COMPLEX WITH INHIBITOR 16D
41, d5c1wA1, 0.9934, 0.53, 1.000, 323, 315, PDE10 COMPLEXED WITH 46-DICHLORO-2-CYCLOPROPYL-5-METHYL-PYRIMIDINE
42, d4wn1B1, 0.9933, 0.53, 1.000, 322, 315, CRYSTAL STRUCTURE OF PDE10A IN COMPLEX WITH 1-METHYL-5-(1-METHYL-3- {[4-(QUINOLIN-2-YL)PHENOXY]METHYL}-1H-PYRAZOL-4-YL)PYRIDIN-2(1H)-ONE
43, d4msnA1, 0.9933, 0.53, 1.000, 327, 315, CRYSTAL STRUCTURE OF PDE10A2 WITH FRAGMENT ZT0451 (8-NITROQUINOLINE)
44, d3ws8B1, 0.9933, 0.53, 1.000, 322, 315, CRYSTAL STRUCTURE OF PDE10A IN COMPLEX WITH A BENZIMIDAZOLE INHIBITOR
45, d4mshA1, 0.9932, 0.54, 1.000, 326, 315, CRYSTAL STRUCTURE OF PDE10A2 WITH FRAGMENT ZT0143 ((2S)-4-CHLORO-23- DIHYDRO-13-BENZOTHIAZOL-2-AMINE)
46, d2ouyA1, 0.9932, 0.54, 0.997, 328, 315, CRYSTAL STRUCTURE OF PDE10A2 MUTANT D564A IN COMPLEX WITH CAMP.
47, p5xujB_, 0.9931, 0.55, 1.000, 322, 315, CRYSTAL STRUCTURE OF PDE10A IN COMPLEX WITH 7-(4-CHLOROPHENYL)-2- METHYLPYRAZOLO[15-A]PYRIMIDINE
48, d4lm2A1, 0.9931, 0.55, 1.000, 327, 315, CRYSTAL STRUCTURE OF PDE10A2 WITH FRAGMENT ZT462
49, d4llpA1, 0.9931, 0.55, 1.000, 327, 315, CRYSTAL STRUCTURE OF PDE10A2 WITH FRAGMENT ZT401
50, d3ws9B1, 0.9931, 0.54, 1.000, 322, 315, CRYSTAL STRUCTURE OF PDE10A IN COMPLEX WITH A BENZIMDAZOLE INHIBITOR
51, d3wi2A1, 0.9931, 0.54, 1.000, 322, 315, CRYSTAL STRUCTURE OF PDE10A IN COMPLEX WITH INHIBITOR
52, d4lm1A1, 0.9930, 0.55, 1.000, 329, 315, CRYSTAL STRUCTURE OF PDE10A2 WITH FRAGMENT ZT450
53, d3sn7A1, 0.9930, 0.55, 1.000, 329, 315, HIGHLY POTENT SELECTIVE AND ORALLY ACTIVE PHOSPHODIESTARASE 10A INHIBITORS
54, d2weyA1, 0.9930, 0.55, 1.000, 321, 315, HUMAN PDE-PAPAVERINE COMPLEX OBTAINED BY LIGAND SOAKING OF CROSS-LINKED PROTEIN CRYSTALS
55, d2ouqA1, 0.9930, 0.55, 1.000, 322, 315, CRYSTAL STRUCTURE OF PDE10A2 IN COMPLEX WITH GMP
56, d4fcbA1, 0.9929, 0.55, 1.000, 324, 315, POTENT AND SELECTIVE PHOSPHODIESTERASE 10A INHIBITORS
57, d4llxA1, 0.9928, 0.55, 1.000, 321, 315, CRYSTAL STRUCTURE OF PDE10A2 WITH FRAGMENT ZT434
58, d2oupA1, 0.9928, 0.56, 1.000, 327, 315, CRYSTAL STRUCTURE OF PDE10A
59, d5c28A1, 0.9927, 0.56, 1.000, 322, 315, PDE10 COMPLEXED WITH 6-CHLORO-2-CYCLOPROPYL-5-METHYL-PYRIMIDIN-4-AMINE
60, d3sniA1, 0.9927, 0.56, 1.000, 323, 315, HIGHLY POTENT SELECTIVE AND ORALLY ACTIVE PHOSPHODIESTARASE 10A INHIBITORS
61, d2ouvA1, 0.9927, 0.56, 1.000, 321, 315, CRYSTAL STRUCTURE OF PDE10A2 MUTANT OF D564N
62, d4ms0A1, 0.9926, 0.56, 0.997, 323, 315, CRYSTAL STRUCTURE OF PDE10A2 WITH FRAGMENT ZT0443 (6-CHLOROPYRIMIDINE- 24-DIAMINE)
63, d4mrwA1, 0.9926, 0.57, 1.000, 327, 315, CRYSTAL STRUCTURE OF PDE10A2 WITH FRAGMENT ZT0120 (7-CHLOROQUINOLIN-4- OL)
64, d4llkA1, 0.9926, 0.56, 1.000, 327, 315, CRYSTAL STRUCTURE OF PDE10A2 WITH FRAGMENT ZT217
65, d4lljA1, 0.9926, 0.57, 1.000, 327, 315, CRYSTAL STRUCTURE OF PDE10A2 WITH FRAGMENT ZT214
66, d4ajmD_, 0.9926, 0.57, 1.000, 327, 315, DEVELOPMENT OF A PLATE-BASED OPTICAL BIOSENSOR METHODOLOGY TO IDENTIFY PDE10 FRAGMENT INHIBITORS
67, d4mseA1, 0.9925, 0.42, 1.000, 320, 314, CRYSTAL STRUCTURE OF PDE10A2 WITH FRAGMENT ZT1597 (2-({[(2S)-2-METHYL- 23-DIHYDRO-13-BENZOTHIAZOL-5-YL]OXY}METHYL)QUINOLINE)
68, d4lkqA1, 0.9925, 0.57, 1.000, 327, 315, CRYSTAL STRUCTURE OF PDE10A2 WITH FRAGMENT ZT017
69, d4fcdA1, 0.9925, 0.57, 1.000, 327, 315, POTENT AND SELECTIVE PHOSPHODIESTERASE 10A INHIBITORS
70, d2ourA1, 0.9925, 0.57, 1.000, 321, 315, CRYSTAL STRUCTURE OF PDE10A2 MUTANT D674A IN COMPLEX WITH CAMP
71, d4mrzA1, 0.9924, 0.57, 0.997, 322, 315, CRYSTAL STRUCTURE OF PDE10A2 WITH FRAGMENT ZT0429 (4-METHYL-3- NITROPYRIDIN-2-AMINE)
72, d4lm4A1, 0.9924, 0.57, 1.000, 327, 315, CRYSTAL STRUCTURE OF PDE10A2 WITH FRAGMENT ZT902
73, d4lm3A1, 0.9924, 0.57, 1.000, 327, 315, CRYSTAL STRUCTURE OF PDE10A2 WITH FRAGMENT ZT464
74, d3snlA1, 0.9924, 0.57, 1.000, 328, 315, HIGHLY POTENT SELECTIVE AND ORALLY ACTIVE PHOSPHODIESTARASE 10A INHIBITORS
75, d2weyB1, 0.9924, 0.57, 1.000, 321, 315, HUMAN PDE-PAPAVERINE COMPLEX OBTAINED BY LIGAND SOAKING OF CROSS-LINKED PROTEIN CRYSTALS
76, d4lm0A1, 0.9923, 0.57, 1.000, 322, 315, CRYSTAL STRUCTURE OF PDE10A2 WITH FRAGMENT ZT448
77, d4msaA1, 0.9922, 0.58, 1.000, 327, 315, CRYSTAL STRUCTURE OF PDE10A2 WITH FRAGMENT ZT0449 (5-NITRO-1H- BENZIMIDAZOLE)
78, d2ounA1, 0.9922, 0.58, 1.000, 327, 315, CRYSTAL STRUCTURE OF PDE10A2 IN COMPLEX WITH AMP
79, d2ouuA1, 0.9921, 0.58, 1.000, 322, 315, CRYSTAL STRUCTURE OF PDE10A2 MUTANT D674A IN COMPLEX WITH CGMP
80, d2ousA1, 0.9920, 0.59, 0.997, 326, 315, CRYSTAL STRUCTURE OF PDE10A2 MUTANT D674A
81, d5c2hB1, 0.9918, 0.59, 0.997, 323, 315, PDE10 COMPLEXED WITH 6-CHLORO-N-[(24-DIMETHYLTHIAZOL-5-YL)METHYL]-5- METHYL-2-[3-(2-QUINOLYL)PROPOXY]PYRIMIDIN-4-AMINE
82, d2y0jA_, 0.9915, 0.47, 1.000, 320, 314, TRIAZOLOQUINAZOLINES AS A NOVEL CLASS OF PHOSPHODIESTERASE 10A (PDE10A) INHIBITORS PART 2 LEAD-OPTIMISATION.
83, d4ajgA1, 0.9912, 0.48, 1.000, 314, 314, IDENTIFICATION AND STRUCTURAL CHARACTERIZATION OF PDE10 FRAGMENT INHIBITORS
84, d3ui7A_, 0.9899, 0.49, 1.000, 320, 314, DISCOVERY OF ORALLY ACTIVE PYRAZOLOQUINOLINE AS A POTENT PDE10 INHIBITOR FOR THE MANAGEMENT OF SCHIZOPHRENIA
85, d5uwfC1, 0.9896, 0.55, 1.000, 315, 314, CRYSTAL STRUCTURE OF HUMAN PDE10A IN COMPLEX WITH INHIBITOR 16D
86, d4ajfA1, 0.9896, 0.56, 1.000, 320, 314, IDENTIFICATION AND STRUCTURAL CHARACTERIZATION OF PDE10 FRAGMENT INHIBITORS
87, d3wylB_, 0.9886, 0.56, 1.000, 325, 314, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF PDE10A COMPLEXED WITH 5- METHOXY-3-(1-PHENYL-1H-PYRAZOL-5-YL)-1-(3-(TRIFLUOROMETHYL)PHENYL) PYRIDAZIN-4(1H)-ONE
88, d4aelA1, 0.9878, 0.47, 1.000, 313, 313, PDE10A IN COMPLEX WITH THE INHIBITOR AZ5
89, d4xy2B1, 0.9872, 0.50, 1.000, 319, 313, CRYSTAL STRUCTURE OF PDE10A IN COMPLEX WITH ASP9436
90, p5dh5A_, 0.9862, 0.53, 1.000, 320, 313, PDE10 COMPLEXED WITH N-[(1-METHYLPYRAZOL-4-YL)METHYL]-5-[[(1S2S)-2- (2-PYRIDYL)CYCLOPROPYL]METHOXY]PYRAZOLO[15-A]PYRIMIDIN-7-AMINE
91, d4bbxB_, 0.9860, 0.43, 1.000, 321, 312, DISCOVERY OF A POTENT SELECTIVE AND ORALLY ACTIVE PDE10A INHIBITOR FOR THE TREATMENT OF SCHIZOPHRENIA
92, d4ajmA1, 0.9857, 0.44, 1.000, 312, 312, DEVELOPMENT OF A PLATE-BASED OPTICAL BIOSENSOR METHODOLOGY TO IDENTIFY PDE10 FRAGMENT INHIBITORS
93, d5k9rA_, 0.9856, 0.45, 1.000, 318, 312, PDE10A WITH IMIDAZOPYRAZINE INHIBITOR
94, d5k9rB_, 0.9843, 0.46, 0.997, 312, 312, PDE10A WITH IMIDAZOPYRAZINE INHIBITOR
95, d4bbxA_, 0.9843, 0.52, 0.997, 312, 312, DISCOVERY OF A POTENT SELECTIVE AND ORALLY ACTIVE PDE10A INHIBITOR FOR THE TREATMENT OF SCHIZOPHRENIA
96, d4mscB1, 0.9738, 0.52, 1.000, 312, 312, CRYSTAL STRUCTURE OF PDE10A2 WITH FRAGMENT ZT1595 (2-[(QUINOLIN-7- YLOXY)METHYL]QUINOLINE)
97, d4ajfD1, 0.9738, 1.22, 1.000, 326, 315, IDENTIFICATION AND STRUCTURAL CHARACTERIZATION OF PDE10 FRAGMENT INHIBITORS
98, d4mshB1, 0.9734, 1.21, 1.000, 322, 315, CRYSTAL STRUCTURE OF PDE10A2 WITH FRAGMENT ZT0143 ((2S)-4-CHLORO-23- DIHYDRO-13-BENZOTHIAZOL-2-AMINE)
99, d4mseB1, 0.9731, 1.23, 1.000, 324, 315, CRYSTAL STRUCTURE OF PDE10A2 WITH FRAGMENT ZT1597 (2-({[(2S)-2-METHYL- 23-DIHYDRO-13-BENZOTHIAZOL-5-YL]OXY}METHYL)QUINOLINE)
100, d5c2hA_, 0.9728, 1.22, 1.000, 326, 315, PDE10 COMPLEXED WITH 6-CHLORO-N-[(24-DIMETHYLTHIAZOL-5-YL)METHYL]-5- METHYL-2-[3-(2-QUINOLYL)PROPOXY]PYRIMIDIN-4-AMINE
101, d4msnB1, 0.9728, 0.46, 1.000, 308, 308, CRYSTAL STRUCTURE OF PDE10A2 WITH FRAGMENT ZT0451 (8-NITROQUINOLINE)
102, d4mrwB1, 0.9713, 1.24, 1.000, 324, 315, CRYSTAL STRUCTURE OF PDE10A2 WITH FRAGMENT ZT0120 (7-CHLOROQUINOLIN-4- OL)
103, d4ms0B_, 0.9712, 1.30, 1.000, 323, 315, CRYSTAL STRUCTURE OF PDE10A2 WITH FRAGMENT ZT0443 (6-CHLOROPYRIMIDINE- 24-DIAMINE)
104, d4msaB1, 0.9711, 1.30, 1.000, 324, 315, CRYSTAL STRUCTURE OF PDE10A2 WITH FRAGMENT ZT0449 (5-NITRO-1H- BENZIMIDAZOLE)
105, d4lm2B1, 0.9711, 1.29, 1.000, 326, 315, CRYSTAL STRUCTURE OF PDE10A2 WITH FRAGMENT ZT462
106, d4mrzB1, 0.9709, 1.30, 1.000, 326, 315, CRYSTAL STRUCTURE OF PDE10A2 WITH FRAGMENT ZT0429 (4-METHYL-3- NITROPYRIDIN-2-AMINE)
107, d4llxB1, 0.9709, 1.29, 1.000, 326, 315, CRYSTAL STRUCTURE OF PDE10A2 WITH FRAGMENT ZT434
108, d4lkqB1, 0.9709, 1.30, 1.000, 326, 315, CRYSTAL STRUCTURE OF PDE10A2 WITH FRAGMENT ZT017
109, d4lm3B1, 0.9708, 1.30, 1.000, 326, 315, CRYSTAL STRUCTURE OF PDE10A2 WITH FRAGMENT ZT464
110, d4llkB1, 0.9708, 1.30, 1.000, 326, 315, CRYSTAL STRUCTURE OF PDE10A2 WITH FRAGMENT ZT217
111, d4lm4B1, 0.9707, 1.31, 1.000, 326, 315, CRYSTAL STRUCTURE OF PDE10A2 WITH FRAGMENT ZT902
112, d4lm1B1, 0.9707, 1.30, 1.000, 326, 315, CRYSTAL STRUCTURE OF PDE10A2 WITH FRAGMENT ZT450
113, d4lm0B1, 0.9707, 1.31, 1.000, 323, 315, CRYSTAL STRUCTURE OF PDE10A2 WITH FRAGMENT ZT448
114, d2oupB1, 0.9707, 1.30, 1.000, 326, 315, CRYSTAL STRUCTURE OF PDE10A
115, d2ouvB1, 0.9706, 1.30, 1.000, 322, 315, CRYSTAL STRUCTURE OF PDE10A2 MUTANT OF D564N
116, d5dh4A_, 0.9698, 1.30, 0.997, 325, 315, PDE10 COMPLEXED WITH 5-CHLORO-N-[(24-DIMETHYLTHIAZOL-5-YL) METHYL]PYRAZOLO[15-A]PYRIMIDIN-7-AMINE
117, d2ousB1, 0.9696, 0.46, 1.000, 307, 307, CRYSTAL STRUCTURE OF PDE10A2 MUTANT D674A
118, d2ounB1, 0.9694, 1.32, 0.997, 326, 315, CRYSTAL STRUCTURE OF PDE10A2 IN COMPLEX WITH AMP
119, d4dffA_, 0.9688, 1.33, 1.000, 325, 315, THE SAR DEVELOPMENT OF DIHYDROIMIDAZOISOQUINOLINE DERIVATIVES AS PHOSPHODIESTERASE 10A INHIBITORS FOR THE TREATMENT OF SCHIZOPHRENIA
120, d4mvhB_, 0.9668, 0.51, 1.000, 307, 307, CRYSTAL STRUCTURE OF PDE10A WITH NOVEL KETO-BENZIMIDAZOLE INHIBITOR
121, d4p1rB_, 0.9663, 0.72, 1.000, 308, 308, CRYSTAL STRUCTURE OF PDE10A WITH IMIDAZO[45-B]PYRIDINES AS POTENT AND SELECTIVE INHIBITORS
122, d4heuB_, 0.9662, 0.74, 1.000, 308, 308, CRYSTAL STRUCTURE OF PDE10A WITH A BIARYL ETHER INHIBITOR ((1-(3-(4- ((1H-BENZO[D]IMIDAZOL-2-YL)AMINO)PHENOXY)PYRIDIN-2-YL)PIPERIDIN-4- YL)METHANOL)
123, d4hf4B_, 0.9659, 0.74, 1.000, 308, 308, CRYSTAL STRUCTURE OF PDE10A WITH A BIARYL ETHER INHIBITOR (1-(1-(3-(4- (BENZO[D]THIAZOL-2-YLAMINO)PHENOXY)PYRAZIN-2-YL)PIPERIDIN-4-YL) ETHANOL)
124, d4hf4A_, 0.9656, 0.75, 1.000, 308, 308, CRYSTAL STRUCTURE OF PDE10A WITH A BIARYL ETHER INHIBITOR (1-(1-(3-(4- (BENZO[D]THIAZOL-2-YLAMINO)PHENOXY)PYRAZIN-2-YL)PIPERIDIN-4-YL) ETHANOL)
125, d4heuA_, 0.9656, 1.20, 1.000, 318, 310, CRYSTAL STRUCTURE OF PDE10A WITH A BIARYL ETHER INHIBITOR ((1-(3-(4- ((1H-BENZO[D]IMIDAZOL-2-YL)AMINO)PHENOXY)PYRIDIN-2-YL)PIPERIDIN-4- YL)METHANOL)
126, d4p0nB_, 0.9655, 1.19, 1.000, 318, 310, CRYSTAL STRUCTURE OF PDE10A WITH A NOVEL IMIDAZO[45-B]PYRIDINE INHIBITOR
127, d4muwA_, 0.9654, 0.76, 1.000, 308, 308, CRYSTAL STRUCTURE OF PDE10A WITH NOVEL KETO-BENZIMIDAZOLE INHIBITOR
128, d5c29A_, 0.9653, 1.21, 1.000, 318, 310, PDE10 COMPLEXED WITH 6-CHLORO-2-CYCLOPROPYL-5-METHYL-N-PROPYL- PYRIMIDIN-4-AMINE
129, d4ddlB_, 0.9653, 0.52, 1.000, 307, 306, PDE10A CRYSTAL STRUCTURE COMPLEXED WITH NOVEL INHIBITOR
130, d4p1rA_, 0.9651, 0.77, 1.000, 308, 308, CRYSTAL STRUCTURE OF PDE10A WITH IMIDAZO[45-B]PYRIDINES AS POTENT AND SELECTIVE INHIBITORS
131, d4ddlA_, 0.9649, 1.20, 1.000, 318, 310, PDE10A CRYSTAL STRUCTURE COMPLEXED WITH NOVEL INHIBITOR
132, d5edgA_, 0.9633, 1.21, 1.000, 318, 310, HUMAN PDE10A IN COMPLEX WITH 3-(2-CHLORO-5-PHENYL-3H-IMIDAZOL-4-YL)-1- (3-TRIFLUOROMETHOXY-PHENYL)-1H-PYRIDAZIN-4-ONE AT 2.30A
133, d5edeA_, 0.9630, 1.07, 0.997, 312, 309, HUMAN PDE10A IN COMPLEX WITH 1-(4-CHLORO-PHENYL)-3-METHYL-1H-THIENO[2 3-C]PYRAZOLE-5-CARBOXYLIC ACID (TETRAHYDRO-FURAN-2-YLMETHYL)-AMIDE AT 2.2A
134, d4tpmB_, 0.9629, 1.10, 0.997, 313, 309, CRYSTAL STRUCTURE OF 2-(3-ALKOXY-1-AZETIDINYL) QUINOLINES AS PDE10A INHIBITORS
135, d4lljB1, 0.9629, 0.75, 1.000, 307, 307, CRYSTAL STRUCTURE OF PDE10A2 WITH FRAGMENT ZT214
136, d4tppB_, 0.9627, 1.26, 1.000, 321, 312, 2-(3-ALKOXY-1-AZETIDINYL) QUINOLINES AS NOVEL PDE10A INHIBITORS
137, d5edgB1, 0.9626, 0.75, 1.000, 307, 307, HUMAN PDE10A IN COMPLEX WITH 3-(2-CHLORO-5-PHENYL-3H-IMIDAZOL-4-YL)-1- (3-TRIFLUOROMETHOXY-PHENYL)-1H-PYRIDAZIN-4-ONE AT 2.30A
138, d4mvhA_, 0.9625, 1.11, 0.997, 313, 309, CRYSTAL STRUCTURE OF PDE10A WITH NOVEL KETO-BENZIMIDAZOLE INHIBITOR
139, d5edhA_, 0.9623, 0.77, 1.000, 307, 307, HUMAN PDE10A 8-ETHYL-5-METHYL-2-[2-(2-METHYL-5-PYRROLIDIN-1-YL-124- TRIAZOL-3-YL)ETHYL]-[124]TRIAZOLO[15-C]PYRIMIDINE 2.03A H3 RFREE=22.7%
140, d5edgC_, 0.9623, 1.11, 1.000, 311, 309, HUMAN PDE10A IN COMPLEX WITH 3-(2-CHLORO-5-PHENYL-3H-IMIDAZOL-4-YL)-1- (3-TRIFLUOROMETHOXY-PHENYL)-1H-PYRIDAZIN-4-ONE AT 2.30A
141, d5edeC_, 0.9622, 1.08, 0.997, 312, 309, HUMAN PDE10A IN COMPLEX WITH 1-(4-CHLORO-PHENYL)-3-METHYL-1H-THIENO[2 3-C]PYRAZOLE-5-CARBOXYLIC ACID (TETRAHYDRO-FURAN-2-YLMETHYL)-AMIDE AT 2.2A
142, d5i2rA_, 0.9621, 1.09, 0.997, 312, 309, HUMAN PDE10A IN COMPLEX WITH 3-(2-PHENYLPYRAZOL-3-YL)-1-[3- (TRIFLUOROMETHOXY)PHENYL]PYRIDAZIN-4-ONE
143, d5ediA_, 0.9621, 1.12, 1.000, 312, 309, HUMAN PDE10A 6-CHLORO-58-DIMETHYL-2-[2-(2-METHYL-5-PYRROLIDIN-1-YL- 2H-[124]TRIAZOL-3-YL)-ETHYL]-[124]TRIAZOLO[15-A]PYRIDINE 2.20A H3 RFREE=23.5%
144, d4p0nA_, 0.9621, 1.12, 0.997, 312, 309, CRYSTAL STRUCTURE OF PDE10A WITH A NOVEL IMIDAZO[45-B]PYRIDINE INHIBITOR
145, d5ediC_, 0.9619, 0.78, 1.000, 307, 307, HUMAN PDE10A 6-CHLORO-58-DIMETHYL-2-[2-(2-METHYL-5-PYRROLIDIN-1-YL- 2H-[124]TRIAZOL-3-YL)-ETHYL]-[124]TRIAZOLO[15-A]PYRIDINE 2.20A H3 RFREE=23.5%
146, d5edhC_, 0.9619, 1.10, 0.997, 312, 309, HUMAN PDE10A 8-ETHYL-5-METHYL-2-[2-(2-METHYL-5-PYRROLIDIN-1-YL-124- TRIAZOL-3-YL)ETHYL]-[124]TRIAZOLO[15-C]PYRIMIDINE 2.03A H3 RFREE=22.7%
147, d3uuoA_, 0.9619, 1.10, 1.000, 312, 309, THE DISCOVERY OF POTENT SELECTIVITY AND ORALLY BIOAVAILABLE PYROZOLOQUINOLINES AS PDE10 INHIBITORS FOR THE TREATMENT OF SCHIZOPHRENIA
148, d3lxgA_, 0.9618, 0.53, 1.000, 305, 305, CRYSTAL STRUCTURE OF RAT PHOSPHODIESTERASE 10A IN COMPLEX WITH LIGAND WEB-3
149, d5ediB1, 0.9617, 0.78, 0.964, 308, 307, HUMAN PDE10A 6-CHLORO-58-DIMETHYL-2-[2-(2-METHYL-5-PYRROLIDIN-1-YL- 2H-[124]TRIAZOL-3-YL)-ETHYL]-[124]TRIAZOLO[15-A]PYRIDINE 2.20A H3 RFREE=23.5%
150, d5i2rB_, 0.9615, 1.13, 0.997, 318, 309, HUMAN PDE10A IN COMPLEX WITH 3-(2-PHENYLPYRAZOL-3-YL)-1-[3- (TRIFLUOROMETHOXY)PHENYL]PYRIDAZIN-4-ONE
151, d5edeB1, 0.9615, 1.16, 1.000, 316, 309, HUMAN PDE10A IN COMPLEX WITH 1-(4-CHLORO-PHENYL)-3-METHYL-1H-THIENO[2 3-C]PYRAZOLE-5-CARBOXYLIC ACID (TETRAHYDRO-FURAN-2-YLMETHYL)-AMIDE AT 2.2A
152, d5i2rC_, 0.9614, 1.14, 0.997, 312, 309, HUMAN PDE10A IN COMPLEX WITH 3-(2-PHENYLPYRAZOL-3-YL)-1-[3- (TRIFLUOROMETHOXY)PHENYL]PYRIDAZIN-4-ONE
153, d5edhB1, 0.9614, 1.12, 1.000, 312, 309, HUMAN PDE10A 8-ETHYL-5-METHYL-2-[2-(2-METHYL-5-PYRROLIDIN-1-YL-124- TRIAZOL-3-YL)ETHYL]-[124]TRIAZOLO[15-C]PYRIMIDINE 2.03A H3 RFREE=22.7%
154, d3jwqA_, 0.9607, 1.14, 1.000, 312, 309, CRYSTAL STRUCTURE OF CHIMERIC PDE5/PDE6 CATALYTIC DOMAIN COMPLEXED WITH SILDENAFIL
155, d3jwqC1, 0.9595, 1.43, 0.420, 324, 314, CRYSTAL STRUCTURE OF CHIMERIC PDE5/PDE6 CATALYTIC DOMAIN COMPLEXED WITH SILDENAFIL
156, d3jwqB_, 0.9595, 1.45, 0.420, 325, 314, CRYSTAL STRUCTURE OF CHIMERIC PDE5/PDE6 CATALYTIC DOMAIN COMPLEXED WITH SILDENAFIL
157, d1t9sB_, 0.9595, 1.45, 0.420, 324, 314, CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 5A IN COMPLEX WITH GMP
158, d4muwB_, 0.9594, 1.39, 0.387, 326, 313, CRYSTAL STRUCTURE OF PDE10A WITH NOVEL KETO-BENZIMIDAZOLE INHIBITOR
159, d5edgD1, 0.9590, 0.76, 1.000, 306, 306, HUMAN PDE10A IN COMPLEX WITH 3-(2-CHLORO-5-PHENYL-3H-IMIDAZOL-4-YL)-1- (3-TRIFLUOROMETHOXY-PHENYL)-1H-PYRIDAZIN-4-ONE AT 2.30A
160, d5jo3B_, 0.9588, 1.09, 0.994, 311, 308, PDE5A FOR NAV1.7
161, d3jwrB1, 0.9588, 1.41, 0.387, 323, 313, CRYSTAL STRUCTURE OF CHIMERIC PDE5/PDE6 CATALYTIC DOMAIN COMPLEXED WITH 3-ISOBUTYL-1-METHYLXANTHINE (IBMX) AND PDE6 GAMMA-SUBUNIT INHIBITORY PEPTIDE 70-87.
162, p3jabO_, 0.9588, 1.46, 0.420, 325, 314, DOMAIN ORGANIZATION AND CONFORMATIONAL PLASTICITY OF THE G PROTEIN EFFECTOR PDE6
163, p3jabC_, 0.9588, 1.46, 0.420, 328, 314, DOMAIN ORGANIZATION AND CONFORMATIONAL PLASTICITY OF THE G PROTEIN EFFECTOR PDE6
164, d2chmA1, 0.9588, 1.46, 0.420, 328, 314, CRYSTAL STRUCTURE OF N2 SUBSTITUTED PYRAZOLO PYRIMIDINONES- A FLIPPED BINDING MODE IN PDE5
165, d1tbfA_, 0.9588, 1.46, 0.420, 328, 314, CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 5A IN COMPLEX WITH SILDENAFIL
166, d5edeD1, 0.9587, 1.42, 0.387, 323, 313, HUMAN PDE10A IN COMPLEX WITH 1-(4-CHLORO-PHENYL)-3-METHYL-1H-THIENO[2 3-C]PYRAZOLE-5-CARBOXYLIC ACID (TETRAHYDRO-FURAN-2-YLMETHYL)-AMIDE AT 2.2A
167, p3jwrA_, 0.9587, 1.41, 0.390, 326, 313, CRYSTAL STRUCTURE OF CHIMERIC PDE5/PDE6 CATALYTIC DOMAIN COMPLEXED WITH 3-ISOBUTYL-1-METHYLXANTHINE (IBMX) AND PDE6 GAMMA-SUBUNIT INHIBITORY PEPTIDE 70-87.
168, d1xozA_, 0.9587, 1.11, 0.994, 311, 308, CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 5A IN COMPLEX WITH TADALAFIL
169, d3hdzA_, 0.9586, 1.47, 0.420, 323, 314, IDENTIFICATION SYNTHESIS AND SAR OF AMINO SUBSTITUTED PYRIDO[3 2B]PRYAZIONES AS POTENT AND SELECTIVE PDE5 INHIBITORS
170, d5ediD_, 0.9585, 1.42, 0.387, 326, 313, HUMAN PDE10A 6-CHLORO-58-DIMETHYL-2-[2-(2-METHYL-5-PYRROLIDIN-1-YL- 2H-[124]TRIAZOL-3-YL)-ETHYL]-[124]TRIAZOLO[15-A]PYRIDINE 2.20A H3 RFREE=23.5%
171, d2o8hA_, 0.9585, 1.42, 0.387, 323, 313, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF RAT PHOSPHODIESTERASE 10A
172, d5edhD1, 0.9584, 1.11, 0.994, 316, 308, HUMAN PDE10A 8-ETHYL-5-METHYL-2-[2-(2-METHYL-5-PYRROLIDIN-1-YL-124- TRIAZOL-3-YL)ETHYL]-[124]TRIAZOLO[15-C]PYRIMIDINE 2.03A H3 RFREE=22.7%
173, d3jwqD_, 0.9584, 0.79, 0.967, 307, 306, CRYSTAL STRUCTURE OF CHIMERIC PDE5/PDE6 CATALYTIC DOMAIN COMPLEXED WITH SILDENAFIL
174, d5i2rD1, 0.9578, 1.11, 0.997, 310, 308, HUMAN PDE10A IN COMPLEX WITH 3-(2-PHENYLPYRAZOL-3-YL)-1-[3- (TRIFLUOROMETHOXY)PHENYL]PYRIDAZIN-4-ONE
175, d1t9sA_, 0.9578, 1.47, 0.424, 323, 314, CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 5A IN COMPLEX WITH GMP
176, d3tggA_, 0.9575, 1.14, 0.997, 311, 308, A NOVEL SERIES OF POTENT AND SELECTIVE PDE5 INHIBITOR2
177, d3tgeA_, 0.9575, 1.43, 0.387, 326, 313, A NOVEL SERIES OF POTENT AND SELECTIVE PDE5 INHIBITOR1
178, d3hc8A_, 0.9574, 1.43, 0.390, 324, 313, INVESTIGATION OF AMINOPYRIDIOPYRAZINONES AS PDE5 INHIBITORS: EVALUATION OF MODIFICATIONS TO THE CENTRAL RING SYSTEM.
179, d4phwA_, 0.9571, 1.43, 0.390, 324, 313, CRYSTAL STRUCTURE OF PDE10A WITH 1H-BENZIMIDAZOL-2-YL(4-((3- (TETRAHYDRO-2H-PYRAN-4-YL)-2-PYRIDINYL)OXY)PHENYL)METHANONE
180, d4phwB_, 0.9570, 1.43, 0.390, 324, 313, CRYSTAL STRUCTURE OF PDE10A WITH 1H-BENZIMIDAZOL-2-YL(4-((3- (TETRAHYDRO-2H-PYRAN-4-YL)-2-PYRIDINYL)OXY)PHENYL)METHANONE
181, d1xp0A_, 0.9569, 0.73, 1.000, 305, 305, CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 5A IN COMPLEX WITH VARDENAFIL
182, d3hqzA_, 0.9558, 0.73, 1.000, 305, 305, DISCOVERY OF NOVEL INHIBITORS OF PDE10A
183, d3hr1A_, 0.9555, 1.44, 0.387, 326, 313, DISCOVERY OF NOVEL INHIBITORS OF PDE10A
184, d2ovyA_, 0.9553, 0.77, 0.964, 305, 305, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF RAT PHOSPHODIESTERASE 10A
185, d3hqyA_, 0.9552, 0.78, 0.964, 305, 305, DISCOVERY OF NOVEL INHIBITORS OF PDE10A
186, d3qpnA_, 0.9551, 0.79, 0.964, 305, 305, STRUCTURE OF PDE10-INHIBITOR COMPLEX
187, d3qpoA_, 0.9550, 0.79, 0.964, 305, 305, STRUCTURE OF PDE10-INHIBITOR COMPLEX
188, d4tppA_, 0.9543, 0.80, 0.964, 305, 305, 2-(3-ALKOXY-1-AZETIDINYL) QUINOLINES AS NOVEL PDE10A INHIBITORS
189, d3qppA_, 0.9540, 0.80, 0.964, 305, 305, STRUCTURE OF PDE10-INHIBITOR COMPLEX
190, d4xy2A1, 0.9539, 0.82, 0.997, 305, 305, CRYSTAL STRUCTURE OF PDE10A IN COMPLEX WITH ASP9436
191, d2ovvA_, 0.9524, 0.83, 0.964, 305, 305, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF RAT PHOSPHODIESTERASE 10A
192, d4fcdB1, 0.9503, 0.60, 1.000, 310, 303, POTENT AND SELECTIVE PHOSPHODIESTERASE 10A INHIBITORS
193, d3snlB1, 0.9503, 0.78, 0.967, 304, 304, HIGHLY POTENT SELECTIVE AND ORALLY ACTIVE PHOSPHODIESTARASE 10A INHIBITORS
194, d4tpmA_, 0.9502, 0.62, 1.000, 308, 302, CRYSTAL STRUCTURE OF 2-(3-ALKOXY-1-AZETIDINYL) QUINOLINES AS PDE10A INHIBITORS
195, d3sn7B1, 0.9502, 0.62, 1.000, 308, 302, HIGHLY POTENT SELECTIVE AND ORALLY ACTIVE PHOSPHODIESTARASE 10A INHIBITORS
196, d4fcbB1, 0.9501, 0.75, 1.000, 303, 303, POTENT AND SELECTIVE PHOSPHODIESTERASE 10A INHIBITORS
197, d3sniB1, 0.9491, 0.62, 1.000, 308, 302, HIGHLY POTENT SELECTIVE AND ORALLY ACTIVE PHOSPHODIESTARASE 10A INHIBITORS
198, d3hqwA_, 0.9488, 0.63, 1.000, 308, 302, DISCOVERY OF NOVEL INHIBITORS OF PDE10A
199, p5xujA_, 0.9470, 0.66, 1.000, 308, 302, CRYSTAL STRUCTURE OF PDE10A IN COMPLEX WITH 7-(4-CHLOROPHENYL)-2- METHYLPYRAZOLO[15-A]PYRIMIDINE
200, d4d08B_, 0.9430, 0.80, 0.967, 303, 303, PDE2A CATALYTIC DOMAIN IN COMPLEX WITH A BRAIN PENETRANT INHIBITOR
201, d5u00D_, 0.9428, 0.62, 1.000, 308, 301, CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 2A IN COMPLEX WITH 33- DIFLUORO-1-[(4-FLUORO-3-IODOPHENYL)CARBONYL]-5-{5-METHYL-[12 4]TRIAZOLO[15-A]PYRIMIDIN-7-YL}PIPERIDINE
202, d4c1iA_, 0.9428, 1.72, 0.361, 337, 313, SELECTIVE INHIBITORS OF PDE2 PDE9 AND PDE10: MODULATORS OF ACTIVITY OF THE CENTRAL NERVOUS SYSTEM
203, d5u7kC_, 0.9427, 1.72, 0.351, 336, 313, PDE2 CATALYTIC DOMAIN COMPLEXED WITH INHIBITORS
204, d4d08A_, 0.9426, 1.70, 0.358, 325, 313, PDE2A CATALYTIC DOMAIN IN COMPLEX WITH A BRAIN PENETRANT INHIBITOR
205, d4jibA1, 0.9422, 1.71, 0.355, 339, 313, CRYSTAL STRUCTURE OF OF PDE2-INHIBITOR COMPLEX
206, p6b97B_, 0.9421, 1.72, 0.358, 339, 313, CRYSTAL STRUCTURE OF PDE2 IN COMPLEX WITH COMPLEX 9
207, d5tzaA1, 0.9421, 1.73, 0.355, 338, 313, CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 2A WITH 3-{5-METHYL-[12 4]TRIAZOLO[15-A]PYRIMIDIN-7-YL-1-[(NAPHTHALENE-2-YL) CARBONYL]PIPERIDINE
208, d5tzwA1, 0.9419, 1.71, 0.358, 348, 313, CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 2A IN COMPLEX WITH 1-[(3 4-DIFLUOROPHENYL)CARBONYL]-33-DIFLUORO-5-{5-METHYL-[12 4]TRIAZOLO[15-A]PYRIMIDIN-7-YL}PIPERIDINE
209, d5u7jA_, 0.9418, 1.71, 0.358, 348, 313, PDE2 CATALYTIC DOMAIN COMPLEXED WITH INHIBITORS
210, d4htzA_, 0.9418, 1.73, 0.355, 338, 313, CRYSTAL STRUCTURE OF PDE2 CATALYTIC DOMAIN IN SPACE GROUP P1
211, d5tzcA1, 0.9416, 1.74, 0.355, 339, 313, CRYSTAL STRUCTURE OF HUMAN PDE2A IN COMPLEX WITH (5S)-1-[(3-BROMO-4- FLUOROPHENYL)CARBONYL]-33-DIFLUORO-5-{5-METHYL-[124]TRIAZOLO[15- A]PYRIMIDIN-7-YL}PIPERIDINE
212, d5u7dC_, 0.9414, 1.74, 0.355, 338, 313, PDE2 CATALYTIC DOMAIN COMPLEXED WITH INHIBITORS
213, d5tzhA1, 0.9414, 1.73, 0.358, 338, 313, CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 2A IN COMPLEX WITH 33- DIFLUORO-1-[(4-FLUOROPHENYL)CARBONYL]-5-{5-METHYL-[124]TRIAZOLO[1 5-A]PYRIMIDIN-7-YL}PIPERIDINE
214, d5tzcC1, 0.9414, 1.74, 0.355, 340, 313, CRYSTAL STRUCTURE OF HUMAN PDE2A IN COMPLEX WITH (5S)-1-[(3-BROMO-4- FLUOROPHENYL)CARBONYL]-33-DIFLUORO-5-{5-METHYL-[124]TRIAZOLO[15- A]PYRIMIDIN-7-YL}PIPERIDINE
215, d5u00A1, 0.9413, 1.74, 0.358, 338, 313, CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 2A IN COMPLEX WITH 33- DIFLUORO-1-[(4-FLUORO-3-IODOPHENYL)CARBONYL]-5-{5-METHYL-[12 4]TRIAZOLO[15-A]PYRIMIDIN-7-YL}PIPERIDINE
216, d3ituA_, 0.9413, 1.75, 0.358, 338, 313, HPDE2A CATALYTIC DOMAIN COMPLEXED WITH IBMX
217, d5u7kA1, 0.9412, 1.75, 0.355, 339, 313, PDE2 CATALYTIC DOMAIN COMPLEXED WITH INHIBITORS
218, d5tzzA1, 0.9411, 1.75, 0.355, 338, 313, CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 2A IN COMPLEX WITH 1-[(3- BROMO-4-FLUOROPHENYL)CARBONYL]-33-DIFLUORO-5-{5-METHYL-[12 4]TRIAZOLO[15-A]PYRIMIDIN-7-YL}PIPERIDINE
219, d5u7lA_, 0.9410, 1.75, 0.355, 338, 313, PDE2 CATALYTIC DOMAIN COMPLEXED WITH INHIBITORS
220, d5u7iB_, 0.9410, 1.76, 0.358, 338, 313, PDE2 CATALYTIC DOMAIN COMPLEXED WITH INHIBITORS
221, d5u7kB1, 0.9409, 1.75, 0.358, 339, 313, PDE2 CATALYTIC DOMAIN COMPLEXED WITH INHIBITORS
222, d5u7iA_, 0.9409, 1.75, 0.355, 339, 313, PDE2 CATALYTIC DOMAIN COMPLEXED WITH INHIBITORS
223, d4d09B_, 0.9409, 1.77, 0.358, 336, 313, PDE2A CATALYTIC DOMAIN IN COMPLEX WITH A BRAIN PENETRANT INHIBITOR
224, d5tzxA1, 0.9408, 1.74, 0.358, 340, 313, CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 2A IN COMPLEX WITH 1-[(3- CHLORO-4-FLUOROPHENYL)CARBONYL]-33-DIFLUORO-5-{5-METHYL-[12 4]TRIAZOLO[15-A]PYRIMIDIN-7-YL}PIPERIDINE
225, d4htxA_, 0.9408, 1.76, 0.358, 338, 313, CRYSTAL STRUCTURE OF PDE2 CATALYTIC DOMAIN IN COMPLEX WITH BAY60-7550
226, d5tzxB_, 0.9407, 1.77, 0.361, 338, 313, CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 2A IN COMPLEX WITH 1-[(3- CHLORO-4-FLUOROPHENYL)CARBONYL]-33-DIFLUORO-5-{5-METHYL-[12 4]TRIAZOLO[15-A]PYRIMIDIN-7-YL}PIPERIDINE
227, d5tzhB1, 0.9407, 1.76, 0.358, 339, 313, CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 2A IN COMPLEX WITH 33- DIFLUORO-1-[(4-FLUOROPHENYL)CARBONYL]-5-{5-METHYL-[124]TRIAZOLO[1 5-A]PYRIMIDIN-7-YL}PIPERIDINE
228, d5tzaB1, 0.9407, 1.75, 0.355, 338, 313, CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 2A WITH 3-{5-METHYL-[12 4]TRIAZOLO[15-A]PYRIMIDIN-7-YL-1-[(NAPHTHALENE-2-YL) CARBONYL]PIPERIDINE
229, d5tz3B1, 0.9407, 1.78, 0.355, 337, 313, CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 2A IN COMPLEX WITH [12 4]TRIAZOLO[15-A]PYRIMIDIN-7-YL}-N-(NAPHTHALENE-2-YL)PIPERIDINE-3- CARBOXAMIDE
230, d5u7jB_, 0.9406, 1.77, 0.355, 338, 313, PDE2 CATALYTIC DOMAIN COMPLEXED WITH INHIBITORS
231, d5tzwB1, 0.9406, 1.78, 0.355, 337, 313, CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 2A IN COMPLEX WITH 1-[(3 4-DIFLUOROPHENYL)CARBONYL]-33-DIFLUORO-5-{5-METHYL-[12 4]TRIAZOLO[15-A]PYRIMIDIN-7-YL}PIPERIDINE
232, d5tz3A1, 0.9406, 1.78, 0.355, 338, 313, CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 2A IN COMPLEX WITH [12 4]TRIAZOLO[15-A]PYRIMIDIN-7-YL}-N-(NAPHTHALENE-2-YL)PIPERIDINE-3- CARBOXAMIDE
233, d5u7lC_, 0.9405, 1.78, 0.358, 336, 313, PDE2 CATALYTIC DOMAIN COMPLEXED WITH INHIBITORS
234, d5u00B1, 0.9404, 1.78, 0.355, 338, 313, CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 2A IN COMPLEX WITH 33- DIFLUORO-1-[(4-FLUORO-3-IODOPHENYL)CARBONYL]-5-{5-METHYL-[12 4]TRIAZOLO[15-A]PYRIMIDIN-7-YL}PIPERIDINE
235, d5tzcB1, 0.9404, 1.76, 0.361, 338, 313, CRYSTAL STRUCTURE OF HUMAN PDE2A IN COMPLEX WITH (5S)-1-[(3-BROMO-4- FLUOROPHENYL)CARBONYL]-33-DIFLUORO-5-{5-METHYL-[124]TRIAZOLO[15- A]PYRIMIDIN-7-YL}PIPERIDINE
236, d5tzzB1, 0.9402, 1.76, 0.355, 338, 313, CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 2A IN COMPLEX WITH 1-[(3- BROMO-4-FLUOROPHENYL)CARBONYL]-33-DIFLUORO-5-{5-METHYL-[12 4]TRIAZOLO[15-A]PYRIMIDIN-7-YL}PIPERIDINE
237, d4htxB_, 0.9402, 1.78, 0.358, 338, 313, CRYSTAL STRUCTURE OF PDE2 CATALYTIC DOMAIN IN COMPLEX WITH BAY60-7550
238, d4d09A_, 0.9402, 1.78, 0.358, 340, 313, PDE2A CATALYTIC DOMAIN IN COMPLEX WITH A BRAIN PENETRANT INHIBITOR
239, d4c1iB_, 0.9402, 1.79, 0.358, 338, 313, SELECTIVE INHIBITORS OF PDE2 PDE9 AND PDE10: MODULATORS OF ACTIVITY OF THE CENTRAL NERVOUS SYSTEM
240, d5xkmC1, 0.9401, 1.79, 0.358, 336, 313, CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 2A IN COMPLEX WITH 6- METHYL-N-(1-(4-(TRIFLUOROMETHOXY)PHENYL)PROPYL)PYRAZOLO[15- A]PYRIMIDINE-3-CARBOXAMIDE
241, d5tzcD_, 0.9399, 1.76, 0.355, 340, 313, CRYSTAL STRUCTURE OF HUMAN PDE2A IN COMPLEX WITH (5S)-1-[(3-BROMO-4- FLUOROPHENYL)CARBONYL]-33-DIFLUORO-5-{5-METHYL-[124]TRIAZOLO[15- A]PYRIMIDIN-7-YL}PIPERIDINE
242, d5xkmB1, 0.9397, 1.57, 0.358, 320, 310, CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 2A IN COMPLEX WITH 6- METHYL-N-(1-(4-(TRIFLUOROMETHOXY)PHENYL)PROPYL)PYRAZOLO[15- A]PYRIMIDINE-3-CARBOXAMIDE
243, d5u00C1, 0.9397, 1.78, 0.355, 340, 313, CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 2A IN COMPLEX WITH 33- DIFLUORO-1-[(4-FLUORO-3-IODOPHENYL)CARBONYL]-5-{5-METHYL-[12 4]TRIAZOLO[15-A]PYRIMIDIN-7-YL}PIPERIDINE
244, d5tzaD_, 0.9390, 1.72, 0.353, 336, 312, CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 2A WITH 3-{5-METHYL-[12 4]TRIAZOLO[15-A]PYRIMIDIN-7-YL-1-[(NAPHTHALENE-2-YL) CARBONYL]PIPERIDINE
245, d4jibD_, 0.9387, 1.79, 0.351, 342, 313, CRYSTAL STRUCTURE OF OF PDE2-INHIBITOR COMPLEX
246, d4jibB_, 0.9386, 1.78, 0.358, 338, 313, CRYSTAL STRUCTURE OF OF PDE2-INHIBITOR COMPLEX
247, d5xkmA_, 0.9385, 1.73, 0.353, 333, 312, CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 2A IN COMPLEX WITH 6- METHYL-N-(1-(4-(TRIFLUOROMETHOXY)PHENYL)PROPYL)PYRAZOLO[15- A]PYRIMIDINE-3-CARBOXAMIDE
248, d5u7dA_, 0.9385, 1.75, 0.353, 335, 312, PDE2 CATALYTIC DOMAIN COMPLEXED WITH INHIBITORS
249, d4htzB_, 0.9384, 1.82, 0.358, 336, 313, CRYSTAL STRUCTURE OF PDE2 CATALYTIC DOMAIN IN SPACE GROUP P1
250, d5c1wB1, 0.9378, 1.82, 0.358, 340, 313, PDE10 COMPLEXED WITH 46-DICHLORO-2-CYCLOPROPYL-5-METHYL-PYRIMIDINE
251, d5xkmD_, 0.9376, 1.80, 0.355, 338, 313, CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 2A IN COMPLEX WITH 6- METHYL-N-(1-(4-(TRIFLUOROMETHOXY)PHENYL)PROPYL)PYRAZOLO[15- A]PYRIMIDINE-3-CARBOXAMIDE
252, p5vp1A_, 0.9376, 1.82, 0.358, 337, 313, DISCOVERY OF CLINICAL CANDIDATE N-{(1S)-1-[3-FLUORO-4- (TRIFLUOROMETHOXY)PHENYL]-2-METHOXYETHYL}-7-METHOXY-2-OXO-23- DIHYDROPYRIDO[23-B]PYRAZINE-4(1H)-CARBOXAMIDE (TAK-915) A HIGHLY POTENT SELECTIVE AND BRAIN-PENETRATING PHOSPHODIESTERASE 2A INHIBITOR FOR THE TREATMENT OF COGNITIVE DISORDERS
253, p6b98A_, 0.9374, 1.26, 1.000, 311, 304, PDE2 IN COMPLEX WITH COMPOUND 1
254, p5vp1B_, 0.9373, 1.84, 0.351, 337, 313, DISCOVERY OF CLINICAL CANDIDATE N-{(1S)-1-[3-FLUORO-4- (TRIFLUOROMETHOXY)PHENYL]-2-METHOXYETHYL}-7-METHOXY-2-OXO-23- DIHYDROPYRIDO[23-B]PYRAZINE-4(1H)-CARBOXAMIDE (TAK-915) A HIGHLY POTENT SELECTIVE AND BRAIN-PENETRATING PHOSPHODIESTERASE 2A INHIBITOR FOR THE TREATMENT OF COGNITIVE DISORDERS
255, d5tz3C_, 0.9363, 1.82, 0.358, 324, 313, CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 2A IN COMPLEX WITH [12 4]TRIAZOLO[15-A]PYRIMIDIN-7-YL}-N-(NAPHTHALENE-2-YL)PIPERIDINE-3- CARBOXAMIDE
256, d4c1iC_, 0.9361, 1.72, 0.359, 344, 312, SELECTIVE INHIBITORS OF PDE2 PDE9 AND PDE10: MODULATORS OF ACTIVITY OF THE CENTRAL NERVOUS SYSTEM
257, d3ituB_, 0.9361, 1.83, 0.355, 331, 313, HPDE2A CATALYTIC DOMAIN COMPLEXED WITH IBMX
258, d5vp0B_, 0.9358, 1.84, 0.351, 334, 313, DISCOVERY OF CLINICAL CANDIDATE N-{(1S)-1-[3-FLUORO-4- (TRIFLUOROMETHOXY)PHENYL]-2-METHOXYETHYL}-7-METHOXY-2-OXO-23- DIHYDROPYRIDO[23-B]PYRAZINE-4(1H)-CARBOXAMIDE (TAK-915) A HIGHLY POTENT SELECTIVE AND BRAIN-PENETRATING PHOSPHODIESTERASE 2A INHIBITOR FOR THE TREATMENT OF COGNITIVE DISORDERS
259, d1z1lA1, 0.9342, 1.65, 0.358, 319, 310, THE CRYSTAL STRUCTURE OF THE PHOSPHODIESTERASE 2A CATALYTIC DOMAIN
260, d5tzzD_, 0.9337, 1.81, 0.359, 333, 312, CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 2A IN COMPLEX WITH 1-[(3- BROMO-4-FLUOROPHENYL)CARBONYL]-33-DIFLUORO-5-{5-METHYL-[12 4]TRIAZOLO[15-A]PYRIMIDIN-7-YL}PIPERIDINE
261, d4c1iD_, 0.9333, 1.85, 0.358, 339, 313, SELECTIVE INHIBITORS OF PDE2 PDE9 AND PDE10: MODULATORS OF ACTIVITY OF THE CENTRAL NERVOUS SYSTEM
262, d5vp0A_, 0.9312, 1.97, 0.358, 336, 313, DISCOVERY OF CLINICAL CANDIDATE N-{(1S)-1-[3-FLUORO-4- (TRIFLUOROMETHOXY)PHENYL]-2-METHOXYETHYL}-7-METHOXY-2-OXO-23- DIHYDROPYRIDO[23-B]PYRAZINE-4(1H)-CARBOXAMIDE (TAK-915) A HIGHLY POTENT SELECTIVE AND BRAIN-PENETRATING PHOSPHODIESTERASE 2A INHIBITOR FOR THE TREATMENT OF COGNITIVE DISORDERS
263, d4gh6B_, 0.9282, 1.72, 0.355, 332, 310, CRYSTAL STRUCTURE OF THE PDE9A CATALYTIC DOMAIN IN COMPLEX WITH INHIBITOR 28
264, d3qi3B_, 0.9282, 1.69, 0.358, 319, 310, CRYSTAL STRUCTURE OF PDE9A(Q453E) IN COMPLEX WITH INHIBITOR BAY73-6691
265, d4e90B1, 0.9277, 1.94, 0.351, 334, 313, HUMAN PHOSPHODIESTERASE 9 IN COMPLEX WITH INHIBITORS
266, d3n3zB_, 0.9274, 1.84, 0.263, 326, 308, CRYSTAL STRUCTURE OF PDE9A (E406A) MUTANT IN COMPLEX WITH IBMX
267, d3jswB1, 0.9274, 1.72, 0.261, 325, 307, HUMAN PDE9 IN COMPLEX WITH SELECTIVE INHIBITOR
268, d3k3hB_, 0.9269, 1.74, 0.264, 324, 307, CRYSTAL STRUCTURE OF THE PDE9A CATALYTIC DOMAIN IN COMPLEX WITH (S)- BAY73-6691
269, d4y8cB_, 0.9266, 1.74, 0.264, 326, 307, CRYSTAL STRUCTURE OF PHOSPHODIESTERASE 9 IN COMPLEX WITH (S)-C33
270, d4g2lB1, 0.9265, 1.75, 0.264, 324, 307, HUMAN PDE9 IN COMPLEX WITH SELECTIVE COMPOUND
271, d4g2jB1, 0.9265, 1.51, 0.266, 320, 305, HUMAN PDE9 IN COMPLEX WITH SELECTIVE COMPOUND
272, d3qi4B_, 0.9265, 1.76, 0.264, 326, 307, CRYSTAL STRUCTURE OF PDE9A(Q453E) IN COMPLEX WITH IBMX
273, d3dynB2, 0.9265, 1.76, 0.264, 324, 307, HUMAN PHOSPHODIESTRASE 9 IN COMPLEX WITH CGMP (ZN INHIBITED)
274, d3dy8B2, 0.9265, 1.76, 0.264, 324, 307, HUMAN PHOSPHODIESTERASE 9 IN COMPLEX WITH PRODUCT 5 -GMP (E+P COMPLEX)
275, d2hd1B_, 0.9264, 1.77, 0.261, 325, 307, CRYSTAL STRUCTURE OF PDE9 IN COMPLEX WITH IBMX
276, d1tbmB_, 0.9264, 1.76, 0.264, 324, 307,  
277, d3jsiB1, 0.9263, 1.76, 0.264, 324, 307, HUMAN PHOSPHODIESTERASE 9 IN COMPLEX WITH INHIBITOR
278, d3dysB2, 0.9263, 1.77, 0.264, 326, 307, HUMAN PHOSPHODIESTRASE-5 GMP COMPLEX (EP) PRODUCED BY SOAKING WITH 20MM CGMP+20 MM MNCL2+20 MM MGCL2 FOR 2 HOURS AND FLASH-COOLED TO LIQUID NITROGEN TEMPERATURE WHEN SUBSTRATE WAS STILL ABUDANT.
279, d4y86B_, 0.9260, 1.77, 0.264, 326, 307, CRYSTAL STRUCTURE OF PDE9 IN COMPLEX WITH RACEMIC INHIBITOR C33
280, d3dyqB2, 0.9260, 1.77, 0.264, 324, 307, HUMAN PHOSPHODIESTRASE 9 (INHIBITED BY OMITTING DIVALENT CATION) IN COMPLEX WITH CGMP
281, d2yy2B_, 0.9257, 1.76, 0.264, 324, 307, CRYSTAL STRUCTURE OF THE HUMAN PHOSPHODIESTERASE 9A CATALYTIC DOMAIN COMPLEXED WITH IBMX
282, d4e90A1, 0.9255, 1.77, 0.264, 326, 307, HUMAN PHOSPHODIESTERASE 9 IN COMPLEX WITH INHIBITORS
283, d4y87B_, 0.9254, 1.77, 0.264, 324, 307, CRYSTAL STRUCTURE OF PHOSPHODIESTERASE 9 IN COMPLEX WITH (R)-C33 (6- {[(1R)-1-(4-CHLOROPHENYL)ETHYL]AMINO}-1-CYCLOPENTYL-15-DIHYDRO-4H- PYRAZOLO[34-D]PYRIMIDIN-4-ONE)
284, d3dylB2, 0.9253, 1.77, 0.264, 324, 307, HUMAN PHOSPHDIESTERASE 9 SUBSTRATE COMPLEX (ES COMPLEX)
285, d3jsiA1, 0.9252, 1.79, 0.264, 324, 307, HUMAN PHOSPHODIESTERASE 9 IN COMPLEX WITH INHIBITOR
286, d3qi3A_, 0.9250, 1.78, 0.264, 326, 307, CRYSTAL STRUCTURE OF PDE9A(Q453E) IN COMPLEX WITH INHIBITOR BAY73-6691
287, d3k3eB_, 0.9250, 1.79, 0.264, 324, 307, CRYSTAL STRUCTURE OF THE PDE9A CATALYTIC DOMAIN IN COMPLEX WITH (R)- BAY73-6691
288, d4gh6A_, 0.9249, 1.81, 0.264, 324, 307, CRYSTAL STRUCTURE OF THE PDE9A CATALYTIC DOMAIN IN COMPLEX WITH INHIBITOR 28
289, d3jswA1, 0.9249, 1.80, 0.261, 325, 307, HUMAN PDE9 IN COMPLEX WITH SELECTIVE INHIBITOR
290, d4g2lA1, 0.9247, 1.48, 0.266, 319, 304, HUMAN PDE9 IN COMPLEX WITH SELECTIVE COMPOUND
291, d4g2jA1, 0.9247, 1.80, 0.264, 326, 307, HUMAN PDE9 IN COMPLEX WITH SELECTIVE COMPOUND
292, d3n3zA_, 0.9247, 1.80, 0.264, 324, 307, CRYSTAL STRUCTURE OF PDE9A (E406A) MUTANT IN COMPLEX WITH IBMX
293, d4y8cA_, 0.9244, 1.81, 0.264, 324, 307, CRYSTAL STRUCTURE OF PHOSPHODIESTERASE 9 IN COMPLEX WITH (S)-C33
294, d3dy8A2, 0.9242, 1.81, 0.264, 324, 307, HUMAN PHOSPHODIESTERASE 9 IN COMPLEX WITH PRODUCT 5 -GMP (E+P COMPLEX)
295, d2r8qB_, 0.9242, 1.82, 0.264, 326, 307, STRUCTURE OF LMJPDEB1 IN COMPLEX WITH IBMX
296, d3dysA_, 0.9241, 1.70, 0.265, 322, 306, HUMAN PHOSPHODIESTRASE-5 GMP COMPLEX (EP) PRODUCED BY SOAKING WITH 20MM CGMP+20 MM MNCL2+20 MM MGCL2 FOR 2 HOURS AND FLASH-COOLED TO LIQUID NITROGEN TEMPERATURE WHEN SUBSTRATE WAS STILL ABUDANT.
297, d3qi4A_, 0.9240, 1.81, 0.264, 324, 307, CRYSTAL STRUCTURE OF PDE9A(Q453E) IN COMPLEX WITH IBMX
298, d2yy2A_, 0.9240, 1.87, 0.276, 335, 312, CRYSTAL STRUCTURE OF THE HUMAN PHOSPHODIESTERASE 9A CATALYTIC DOMAIN COMPLEXED WITH IBMX
299, d4y87A_, 0.9239, 1.81, 0.264, 324, 307, CRYSTAL STRUCTURE OF PHOSPHODIESTERASE 9 IN COMPLEX WITH (R)-C33 (6- {[(1R)-1-(4-CHLOROPHENYL)ETHYL]AMINO}-1-CYCLOPENTYL-15-DIHYDRO-4H- PYRAZOLO[34-D]PYRIMIDIN-4-ONE)
300, d2hd1A_, 0.9239, 1.83, 0.261, 325, 307, CRYSTAL STRUCTURE OF PDE9 IN COMPLEX WITH IBMX
301, d1tbmA_, 0.9239, 1.82, 0.264, 326, 307,  
302, d4qgeB_, 0.9238, 1.71, 0.265, 322, 306, PHOSPHODIESTERASE-9A IN COMPLEX WITH INHIBITOR WYQ-C36D
303, d4y86A_, 0.9237, 1.83, 0.264, 326, 307, CRYSTAL STRUCTURE OF PDE9 IN COMPLEX WITH RACEMIC INHIBITOR C33
304, d4d09C_, 0.9236, 1.83, 0.264, 326, 307, PDE2A CATALYTIC DOMAIN IN COMPLEX WITH A BRAIN PENETRANT INHIBITOR
305, d4qgeA_, 0.9235, 1.83, 0.264, 326, 307, PHOSPHODIESTERASE-9A IN COMPLEX WITH INHIBITOR WYQ-C36D
306, d3dylA2, 0.9235, 1.69, 0.265, 320, 306, HUMAN PHOSPHDIESTERASE 9 SUBSTRATE COMPLEX (ES COMPLEX)
307, d4d08D1, 0.9234, 1.71, 0.265, 322, 306, PDE2A CATALYTIC DOMAIN IN COMPLEX WITH A BRAIN PENETRANT INHIBITOR
308, d3dyqA2, 0.9234, 1.80, 0.354, 329, 308, HUMAN PHOSPHODIESTRASE 9 (INHIBITED BY OMITTING DIVALENT CATION) IN COMPLEX WITH CGMP
309, d3dynA2, 0.9227, 1.72, 0.265, 322, 306, HUMAN PHOSPHODIESTRASE 9 IN COMPLEX WITH CGMP (ZN INHIBITED)
310, d4d08C_, 0.9224, 1.83, 0.264, 324, 307, PDE2A CATALYTIC DOMAIN IN COMPLEX WITH A BRAIN PENETRANT INHIBITOR
311, d5u7jD_, 0.9223, 1.68, 0.353, 332, 306, PDE2 CATALYTIC DOMAIN COMPLEXED WITH INHIBITORS
312, d5tzaC_, 0.9222, 1.83, 0.264, 324, 307, CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 2A WITH 3-{5-METHYL-[12 4]TRIAZOLO[15-A]PYRIMIDIN-7-YL-1-[(NAPHTHALENE-2-YL) CARBONYL]PIPERIDINE
313, d3k3hA_, 0.9222, 1.84, 0.264, 324, 307, CRYSTAL STRUCTURE OF THE PDE9A CATALYTIC DOMAIN IN COMPLEX WITH (S)- BAY73-6691
314, d3ituD_, 0.9222, 1.71, 0.353, 327, 306, HPDE2A CATALYTIC DOMAIN COMPLEXED WITH IBMX
315, d5u7jC_, 0.9220, 1.72, 0.353, 327, 306, PDE2 CATALYTIC DOMAIN COMPLEXED WITH INHIBITORS
316, d5tzwD_, 0.9219, 1.77, 0.355, 328, 307, CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 2A IN COMPLEX WITH 1-[(3 4-DIFLUOROPHENYL)CARBONYL]-33-DIFLUORO-5-{5-METHYL-[12 4]TRIAZOLO[15-A]PYRIMIDIN-7-YL}PIPERIDINE
317, d5tzhD_, 0.9219, 1.60, 0.266, 320, 305, CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 2A IN COMPLEX WITH 33- DIFLUORO-1-[(4-FLUOROPHENYL)CARBONYL]-5-{5-METHYL-[124]TRIAZOLO[1 5-A]PYRIMIDIN-7-YL}PIPERIDINE
318, p3g45A_, 0.9219, 1.72, 0.356, 327, 306, CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 4B WITH REGULATORY DOMAIN AND D155988
319, d5tzwC_, 0.9216, 1.74, 0.356, 327, 306, CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 2A IN COMPLEX WITH 1-[(3 4-DIFLUOROPHENYL)CARBONYL]-33-DIFLUORO-5-{5-METHYL-[12 4]TRIAZOLO[15-A]PYRIMIDIN-7-YL}PIPERIDINE
320, d4htxD_, 0.9215, 1.72, 0.353, 327, 306, CRYSTAL STRUCTURE OF PDE2 CATALYTIC DOMAIN IN COMPLEX WITH BAY60-7550
321, d5u7iD_, 0.9214, 1.72, 0.353, 327, 306, PDE2 CATALYTIC DOMAIN COMPLEXED WITH INHIBITORS
322, p3g45B_, 0.9214, 2.03, 0.244, 371, 311, CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 4B WITH REGULATORY DOMAIN AND D155988
323, d2r8qA_, 0.9214, 2.03, 0.244, 371, 311, STRUCTURE OF LMJPDEB1 IN COMPLEX WITH IBMX
324, d5u7kD_, 0.9213, 1.79, 0.355, 328, 307, PDE2 CATALYTIC DOMAIN COMPLEXED WITH INHIBITORS
325, d5tz3D_, 0.9212, 1.73, 0.356, 327, 306, CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 2A IN COMPLEX WITH [12 4]TRIAZOLO[15-A]PYRIMIDIN-7-YL}-N-(NAPHTHALENE-2-YL)PIPERIDINE-3- CARBOXAMIDE
326, d2ouuB1, 0.9212, 1.73, 0.356, 324, 306, CRYSTAL STRUCTURE OF PDE10A2 MUTANT D674A IN COMPLEX WITH CGMP
327, d5tzxD_, 0.9211, 1.93, 0.245, 370, 310, CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 2A IN COMPLEX WITH 1-[(3- CHLORO-4-FLUOROPHENYL)CARBONYL]-33-DIFLUORO-5-{5-METHYL-[12 4]TRIAZOLO[15-A]PYRIMIDIN-7-YL}PIPERIDINE
328, d4d09D_, 0.9209, 1.92, 0.279, 335, 312, PDE2A CATALYTIC DOMAIN IN COMPLEX WITH A BRAIN PENETRANT INHIBITOR
329, d3k3eA_, 0.9204, 1.92, 0.279, 335, 312, CRYSTAL STRUCTURE OF THE PDE9A CATALYTIC DOMAIN IN COMPLEX WITH (R)- BAY73-6691
330, d4jibC_, 0.9203, 1.73, 0.353, 327, 306, CRYSTAL STRUCTURE OF OF PDE2-INHIBITOR COMPLEX
331, p5laqA_, 0.9199, 1.73, 0.353, 327, 306, CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 4B CATALYTIC DOMAIN WITH INHIBITOR NPD-001
332, d4htzD_, 0.9199, 1.57, 0.997, 309, 303, CRYSTAL STRUCTURE OF PDE2 CATALYTIC DOMAIN IN SPACE GROUP P1
333, d3ituC_, 0.9199, 1.74, 0.353, 328, 306, HPDE2A CATALYTIC DOMAIN COMPLEXED WITH IBMX
334, d2ouqB1, 0.9199, 1.73, 0.356, 326, 306, CRYSTAL STRUCTURE OF PDE10A2 IN COMPLEX WITH GMP
335, d5u7iC_, 0.9198, 1.58, 0.266, 319, 304, PDE2 CATALYTIC DOMAIN COMPLEXED WITH INHIBITORS
336, d1ptwD_, 0.9195, 1.76, 0.353, 327, 306, THE CRYSTAL STRUCTURE OF AMP-BOUND PDE4 SUGGESTS A MECHANISM FOR PHOSPHODIESTERASE CATALYSIS
337, d5ohjA_, 0.9194, 2.05, 0.244, 337, 311, HUMAN PHOSPHODIESTERASE 4B CATALYTIC DOMAIN IN COMPLEX WITH A PYRROLIDINYL INHIBITOR.
338, d4nw7A1, 0.9194, 1.71, 0.361, 326, 305, PDE4 CATALYTIC DOMAIN
339, d2h42A_, 0.9194, 1.77, 0.356, 327, 306, CRYSTAL STRUCTURE OF PDE5 IN COMPLEX WITH SILDENAFIL
340, d5tzzC_, 0.9192, 1.34, 1.000, 306, 299, CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 2A IN COMPLEX WITH 1-[(3- BROMO-4-FLUOROPHENYL)CARBONYL]-33-DIFLUORO-5-{5-METHYL-[12 4]TRIAZOLO[15-A]PYRIMIDIN-7-YL}PIPERIDINE
341, d4myqA_, 0.9192, 1.77, 0.359, 327, 306, SELECTIVE INHIBITION OF THE CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 4B WITH A-33
342, d4htxC_, 0.9192, 2.30, 0.240, 334, 313, CRYSTAL STRUCTURE OF PDE2 CATALYTIC DOMAIN IN COMPLEX WITH BAY60-7550
343, d1ro6A_, 0.9190, 2.08, 0.244, 336, 311, CRYSTAL STRUCTURE OF PDE4B2B COMPLEXED WITH ROLIPRAM (R & S)
344, d5tzhC_, 0.9189, 2.26, 0.240, 342, 313, CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 2A IN COMPLEX WITH 33- DIFLUORO-1-[(4-FLUOROPHENYL)CARBONYL]-5-{5-METHYL-[124]TRIAZOLO[1 5-A]PYRIMIDIN-7-YL}PIPERIDINE
345, d3g4lD_, 0.9187, 1.75, 0.401, 326, 304, CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 4D WITH ROFLUMILAST
346, d1q9mD_, 0.9186, 1.78, 0.359, 327, 306, THREE DIMENSIONAL STRUCTURES OF PDE4D IN COMPLEX WITH ROLIPRAMS AND IMPLICATION ON INHIBITOR SELECTIVITY
347, d1oynD_, 0.9185, 2.28, 0.240, 345, 313, CRYSTAL STRUCTURE OF PDE4D2 IN COMPLEX WITH (RS)-ROLIPRAM
348, d3g4iD_, 0.9184, 1.72, 0.357, 325, 305, CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 4D WITH D155871
349, d1zknD_, 0.9182, 2.29, 0.239, 344, 314, STRUCTURE OF PDE4D2-IBMX
350, d1rkoD_, 0.9182, 1.79, 0.356, 327, 306,  
351, d5tzxC_, 0.9181, 2.15, 0.240, 334, 312, CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 2A IN COMPLEX WITH 1-[(3- CHLORO-4-FLUOROPHENYL)CARBONYL]-33-DIFLUORO-5-{5-METHYL-[12 4]TRIAZOLO[15-A]PYRIMIDIN-7-YL}PIPERIDINE
352, d4htzC_, 0.9180, 2.29, 0.240, 334, 313, CRYSTAL STRUCTURE OF PDE2 CATALYTIC DOMAIN IN SPACE GROUP P1
353, d2fm5D_, 0.9179, 2.29, 0.240, 334, 313, CRYSTAL STRUCTURE OF PDE4D2 IN COMPLEX WITH INHIBITOR L- 869299
354, d3g58D_, 0.9177, 2.31, 0.240, 334, 313, CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 4D WITH D155988/PMNPQ
355, d2fm0D_, 0.9177, 2.30, 0.240, 334, 313, CRYSTAL STRUCTURE OF PDE4D IN COMPLEX WITH L-869298
356, d3hmvA_, 0.9176, 2.30, 0.240, 334, 313, CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 4B2B IN COMPLEX WITH A TETRAHYDROBENZOTHIOPHENE INHIBITOR
357, d3hmvB_, 0.9175, 1.80, 0.356, 327, 306, CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 4B2B IN COMPLEX WITH A TETRAHYDROBENZOTHIOPHENE INHIBITOR
358, d1ro6B_, 0.9173, 1.75, 0.357, 325, 305, CRYSTAL STRUCTURE OF PDE4B2B COMPLEXED WITH ROLIPRAM (R & S)
359, d1uhoA_, 0.9171, 2.30, 0.240, 334, 313, CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 5 COMPLEXED WITH VARDENAFIL(LEVITRA)
360, d2ouyB1, 0.9169, 2.16, 0.240, 345, 312, CRYSTAL STRUCTURE OF PDE10A2 MUTANT D564A IN COMPLEX WITH CAMP.
361, d3g4kD_, 0.9168, 2.30, 0.240, 334, 313, CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 4D WITH ROLIPRAM
362, d2qylA_, 0.9166, 2.22, 0.240, 351, 312, CRYSTAL STRUCTURE OF PDE4B2B IN COMPLEX WITH INHIBITOR NPV
363, d1udtA_, 0.9160, 2.23, 0.240, 351, 312, CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 5 COMPLEXED WITH SILDENAFIL(VIAGRA)
364, p6fdcA_, 0.9159, 2.35, 0.236, 344, 314, CRYSTAL STRUCTURE OF THE PDE4D CATALYTIC DOMAIN IN COMPLEX WITH GEBR- 32A 
365, d5wqaB_, 0.9159, 1.89, 0.398, 313, 304, CRYSTAL STRUCTURE OF PDE4D CATALYTIC DOMAIN COMPLEXED WITH SELAGINPULVILINS K
366, d1ro9A_, 0.9159, 1.43, 0.997, 306, 299, CRYSTAL STRUCTURES OF THE CATALYTIC DOMAIN OF PHOSPHODIESTERASE 4B2B COMPLEXED WITH 8-BR-AMP
367, d5wqaA_, 0.9157, 2.24, 0.240, 333, 312, CRYSTAL STRUCTURE OF PDE4D CATALYTIC DOMAIN COMPLEXED WITH SELAGINPULVILINS K
368, d5c28B1, 0.9157, 2.08, 0.245, 335, 310, PDE10 COMPLEXED WITH 6-CHLORO-2-CYCLOPROPYL-5-METHYL-PYRIMIDIN-4-AMINE
369, d2qykB1, 0.9156, 1.89, 0.398, 313, 304, CRYSTAL STRUCTURE OF PDE4A10 IN COMPLEX WITH INHIBITOR NPV
370, d1f0jA_, 0.9156, 2.17, 0.242, 329, 310, CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 4B2B
371, p6f8tA_, 0.9155, 2.24, 0.242, 334, 310, CRYSTAL STRUCTURE OF THE PDE4D CATALYTIC DOMAIN IN COMPLEX WITH GEBR- 4A 
372, d5ohjB_, 0.9153, 2.39, 0.239, 338, 314, HUMAN PHOSPHODIESTERASE 4B CATALYTIC DOMAIN IN COMPLEX WITH A PYRROLIDINYL INHIBITOR.
373, d3ly2B1, 0.9151, 2.26, 0.242, 334, 310, CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 4B IN COMPLEX WITH A COUMARIN-BASED INHIBITOR
374, d3tvxA1, 0.9150, 1.88, 0.993, 315, 302, THE STRUCTURE OF PDE4A WITH PENTOXIFYLLINE AT 2.84A RESOLUTION
375, p6f8wB_, 0.9149, 2.09, 0.245, 333, 310, CRYSTAL STRUCTURE OF THE PDE4D CATALYTIC DOMAIN IN COMPLEX WITH GEBR- 18A 
376, d1rorA_, 0.9149, 2.39, 0.239, 351, 314, CRYSTAL STRUCTURES OF THE CATALYTIC DOMAIN OF PHOSPHODIESTERASE 4B2B COMPLEXED WITH AMP
377, d2h42B_, 0.9148, 2.18, 0.245, 328, 310, CRYSTAL STRUCTURE OF PDE5 IN COMPLEX WITH SILDENAFIL
378, d2qykA1, 0.9146, 2.02, 0.245, 335, 310, CRYSTAL STRUCTURE OF PDE4A10 IN COMPLEX WITH INHIBITOR NPV
379, d1ptwA_, 0.9146, 2.27, 0.240, 334, 312, THE CRYSTAL STRUCTURE OF AMP-BOUND PDE4 SUGGESTS A MECHANISM FOR PHOSPHODIESTERASE CATALYSIS
380, p6f6uA_, 0.9145, 2.10, 0.245, 333, 310, CRYSTAL STRUCTURE OF THE PDE4D CATALYTIC DOMAIN IN COMPLEX WITH GEBR- 7B 
381, d1so2C_, 0.9145, 2.22, 0.242, 331, 310, CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 3B IN COMPLEX WITH A DIHYDROPYRIDAZINE INHIBITOR
382, d2h42C_, 0.9144, 2.30, 0.240, 338, 313, CRYSTAL STRUCTURE OF PDE5 IN COMPLEX WITH SILDENAFIL
383, d2ourB1, 0.9141, 1.82, 0.401, 317, 304, CRYSTAL STRUCTURE OF PDE10A2 MUTANT D674A IN COMPLEX WITH CAMP
384, d3ly2A1, 0.9140, 2.02, 0.246, 333, 309, CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 4B IN COMPLEX WITH A COUMARIN-BASED INHIBITOR
385, d1uduB_, 0.9140, 2.34, 0.238, 334, 311, CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 5 COMPLEXED WITH TADALAFIL(CIALIS)
386, d1uduA_, 0.9140, 2.23, 0.245, 328, 310, CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 5 COMPLEXED WITH TADALAFIL(CIALIS)
387, d3d3pA_, 0.9139, 1.70, 0.220, 372, 305, CRYSTAL STRUCTURE OF PDE4B CATALYTIC DOMAIN IN COMPLEX WITH A PYRAZOLOPYRIDINE INHIBITOR
388, p5l9hB_, 0.9137, 1.64, 0.397, 317, 302, CRYSTAL STRUCTURE OF T. BRUCEI PDE-B1 CATALYTIC DOMAIN WITH INHIBITOR NPD-340
389, d3o57A_, 0.9137, 1.50, 0.997, 312, 299, CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 4B2B IN COMPLEX WITH A 5- HETEROCYCLE PYRAZOLOPYRIDINE INHIBITOR
390, d4phlB_, 0.9135, 2.29, 0.240, 334, 312, TBRPDEB1-INHIBITOR COMPLEX
391, d2qynA_, 0.9135, 1.97, 0.398, 313, 304, CRYSTAL STRUCTURE OF PDE4D2 IN COMPLEX WITH INHIBITOR NPV
392, d3gwtA_, 0.9134, 1.97, 0.398, 313, 304, CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 4B2B IN COMPLEX WITH A QUINOLINE INHIBITOR
393, d3tvxB1, 0.9133, 2.26, 0.241, 336, 311, THE STRUCTURE OF PDE4A WITH PENTOXIFYLLINE AT 2.84A RESOLUTION
394, d3i8vA1, 0.9132, 2.06, 0.277, 334, 311, CRYSTAL STRUCTURE OF HUMAN PDE4A WITH 4-(3-BUTOXY-4-METHOXYPHENYL) METHYL-2-IMIDAZOLIDONE
395, d1xorB_, 0.9132, 2.27, 0.241, 336, 311, CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 4D IN COMPLEX WITH ZARDAVERINE
396, p6f8vA_, 0.9131, 2.05, 0.280, 332, 311, CRYSTAL STRUCTURE OF THE PDE4D CATALYTIC DOMAIN IN COMPLEX WITH GEBR- 18B 
397, d3o56A_, 0.9131, 1.96, 0.245, 326, 306, CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 4B2B IN COMPLEX WITH A 5- HETEROCYCLE PYRAZOLOPYRIDINE INHIBITOR
398, d3frgA_, 0.9131, 2.27, 0.241, 336, 311, CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 4B2B IN COMPLEX WITH A QUINOLINE INHIBITOR
399, d1tbbB_, 0.9130, 2.14, 0.245, 333, 310, CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 4D IN COMPLEX WITH ROLIPRAM
400, d5g2bA_, 0.9129, 2.13, 0.245, 332, 310, CRYSTAL STRUCTURE OF T. BRUCEI PDE-B1 CATALYTIC DOMAIN WITH INHIBITOR NPD-008
401, d2pw3A_, 0.9129, 1.92, 0.245, 327, 306, STRUCTURE OF THE PDE4D-CAMP COMPLEX
402, d3v9bB_, 0.9128, 2.17, 0.246, 327, 309, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF PDE4D2 WITH (S)-N-(3-{1- [1-(3-CYCLOPROPYLMETHOXY-4-DIFLUOROMETHOXYPHENYL)-2-(1-OXYPYRIDIN-4- YL)-ETHYL]-1H-PYRAZL-3-YL}PHENYL)ACETAMIDE
403, p5l8cA_, 0.9127, 2.41, 0.240, 335, 312, CRYSTAL STRUCTURE OF T. BRUCEI PDE-B1 CATALYTIC DOMAIN WITH INHIBITOR NPD-039
404, p5wh6A_, 0.9126, 2.27, 0.241, 335, 311, CRYSTAL STRUCTURE OF PDE4D2 IN COMPLEX WITH INHIBITOR (S_ZL-N-91) 
405, p5l8yA_, 0.9125, 1.92, 0.245, 326, 306, CRYSTAL STRUCTURE OF T. BRUCEI PDE-B1 CATALYTIC DOMAIN WITH INHIBITOR NPD-937
406, d5g57A_, 0.9123, 2.06, 0.277, 333, 311, CRYSTAL STRUCTURE OF T. BRUCEI PDE-B1 CATALYTIC DOMAIN WITH INHIBITOR NPD-001
407, p4x0fA2, 0.9123, 1.90, 0.242, 327, 306, CRYSTAL STRUCTURE OF CROSSLINK STABILIZED LONG-FORM PDE4B IN COMPLEX WITH (R)-(-)-ROLIPRAM
408, d5h2qA_, 0.9122, 2.05, 0.244, 327, 307, CRYSTAL STRUCTURE OF T BRUCEI PHOSPHODIESTERASE B2 BOUND TO COMPOUND 13E
409, p3g4gA_, 0.9122, 2.07, 0.277, 333, 311, CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 4D WITH REGULATORY DOMAIN AND D155871
410, d1y2cA_, 0.9122, 1.99, 0.245, 326, 306, CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 4D IN COMPLEX WITH 35- DIMETHYL-1-PHENYL-1H-PYRAZOLE-4-CARBOXYLIC ACID ETHYL ESTER
411, d1rorB_, 0.9122, 2.07, 0.277, 333, 311, CRYSTAL STRUCTURES OF THE CATALYTIC DOMAIN OF PHOSPHODIESTERASE 4B2B COMPLEXED WITH AMP
412, d5k1iA_, 0.9121, 2.07, 0.277, 333, 311, PDE4 CRYSTAL STRUCTURE IN COMPLEX WITH SMALL MOLECULE INHIBITOR
413, d5h2rA_, 0.9121, 2.25, 0.244, 333, 311, CRYSTAL STRUCTURE OF T BRUCEI PHOSPHODIESTERASE B2 BOUND TO COMPOUND 15B
414, d3v9bA_, 0.9121, 1.93, 0.298, 329, 309, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF PDE4D2 WITH (S)-N-(3-{1- [1-(3-CYCLOPROPYLMETHOXY-4-DIFLUOROMETHOXYPHENYL)-2-(1-OXYPYRIDIN-4- YL)-ETHYL]-1H-PYRAZL-3-YL}PHENYL)ACETAMIDE
415, d1zknA_, 0.9121, 1.93, 0.245, 338, 306, STRUCTURE OF PDE4D2-IBMX
416, p5wh5A_, 0.9120, 1.87, 0.246, 326, 305, CRYSTAL STRUCTURE OF THE PDE4D2 CATALYTIC DOMAIN IN COMPLEX WITH INHIBITOR (R)-ZL-N-91 
417, d1y2bA_, 0.9120, 2.38, 0.240, 337, 313, CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 4D IN COMPLEX WITH 35- DIMETHYL-1H-PYRAZOLE-4-CARBOXYLIC ACID ETHYL ESTER
418, p5wh6B_, 0.9119, 1.87, 0.246, 322, 305, CRYSTAL STRUCTURE OF PDE4D2 IN COMPLEX WITH INHIBITOR (S_ZL-N-91) 
419, d1oynA_, 0.9119, 1.94, 0.301, 329, 309, CRYSTAL STRUCTURE OF PDE4D2 IN COMPLEX WITH (RS)-ROLIPRAM
420, p5l8yB_, 0.9118, 2.13, 0.244, 331, 308, CRYSTAL STRUCTURE OF T. BRUCEI PDE-B1 CATALYTIC DOMAIN WITH INHIBITOR NPD-937
421, p5g5vB_, 0.9118, 2.40, 0.241, 334, 311, CRYSTAL STRUCTURE OF T. BRUCEI PDE-B1 CATALYTIC DOMAIN WITH INHIBITOR NPD-038
422, d4i15A_, 0.9118, 2.00, 0.245, 326, 306, CRYSTAL STRUCTURE OF TBRPDEB1
423, p3g4gD_, 0.9118, 1.88, 0.246, 326, 305, CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 4D WITH REGULATORY DOMAIN AND D155871
424, d1y2dA_, 0.9118, 1.95, 0.245, 325, 306, CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 4D IN COMPLEX WITH 1-(4- METHOXY-PHENYL)-35-DIMETHYL-1H-PYRAZOLE-4-CARBOXYLIC ACID ETHYL ESTER
425, d1tb7B_, 0.9118, 2.17, 0.243, 334, 309, CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 4D IN COMPLEX WITH AMP
426, p6f8xB_, 0.9117, 2.03, 0.277, 332, 310, CRYSTAL STRUCTURE OF THE PDE4D CATALYTIC DOMAIN IN COMPLEX WITH GEBR- 26G 
427, p5l8cB_, 0.9117, 2.08, 0.277, 332, 311, CRYSTAL STRUCTURE OF T. BRUCEI PDE-B1 CATALYTIC DOMAIN WITH INHIBITOR NPD-039
428, p6fdcB_, 0.9116, 2.07, 0.277, 333, 311, CRYSTAL STRUCTURE OF THE PDE4D CATALYTIC DOMAIN IN COMPLEX WITH GEBR- 32A 
429, p5wh5B_, 0.9115, 1.94, 0.245, 337, 306, CRYSTAL STRUCTURE OF THE PDE4D2 CATALYTIC DOMAIN IN COMPLEX WITH INHIBITOR (R)-ZL-N-91 
430, d3i8vB1, 0.9115, 1.88, 0.246, 326, 305, CRYSTAL STRUCTURE OF HUMAN PDE4A WITH 4-(3-BUTOXY-4-METHOXYPHENYL) METHYL-2-IMIDAZOLIDONE
431, p3g4gC_, 0.9115, 1.89, 0.246, 326, 305, CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 4D WITH REGULATORY DOMAIN AND D155871
432, d1y2eA_, 0.9115, 1.94, 0.252, 324, 305, CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 4D IN COMPLEX WITH 1-(4- AMINO-PHENYL)-35-DIMETHYL-1H-PYRAZOLE-4-CARBOXYLIC ACID ETHYL ESTER
433, d1y2kA_, 0.9114, 2.04, 0.277, 332, 310, CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 4D IN COMPLEX WITH 35- DIMETHYL-1-(3-NITRO-PHENYL)-1H-PYRAZOLE-4-CARBOXYLIC ACID ETHYL ESTER
434, d1xomA_, 0.9114, 1.95, 0.249, 324, 305, CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 4D IN COMPLEX WITH CILOMILAST
435, d4i15B_, 0.9113, 1.95, 0.245, 325, 306, CRYSTAL STRUCTURE OF TBRPDEB1
436, p5l9hA_, 0.9112, 2.07, 0.246, 332, 309, CRYSTAL STRUCTURE OF T. BRUCEI PDE-B1 CATALYTIC DOMAIN WITH INHIBITOR NPD-340
437, d1y2cB_, 0.9112, 1.95, 0.245, 339, 306, CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 4D IN COMPLEX WITH 35- DIMETHYL-1-PHENYL-1H-PYRAZOLE-4-CARBOXYLIC ACID ETHYL ESTER
438, d1xoqA_, 0.9112, 1.89, 0.246, 326, 305, CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 4D IN COMPLEX WITH ROFLUMILAST
439, d1mkdH_, 0.9112, 1.89, 0.246, 326, 305, CRYSTAL STRUCTURE OF PDE4D CATALYTIC DOMAIN AND ZARDAVERINE COMPLEX
440, d1mkdA_, 0.9112, 1.90, 0.246, 326, 305, CRYSTAL STRUCTURE OF PDE4D CATALYTIC DOMAIN AND ZARDAVERINE COMPLEX
441, p6f8tB_, 0.9111, 2.09, 0.277, 333, 311, CRYSTAL STRUCTURE OF THE PDE4D CATALYTIC DOMAIN IN COMPLEX WITH GEBR- 4A 
442, d5k1iG_, 0.9111, 2.09, 0.277, 333, 311, PDE4 CRYSTAL STRUCTURE IN COMPLEX WITH SMALL MOLECULE INHIBITOR
443, d2qynB_, 0.9111, 1.89, 0.246, 326, 305, CRYSTAL STRUCTURE OF PDE4D2 IN COMPLEX WITH INHIBITOR NPV
444, d1y2bB_, 0.9111, 1.90, 0.246, 326, 305, CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 4D IN COMPLEX WITH 35- DIMETHYL-1H-PYRAZOLE-4-CARBOXYLIC ACID ETHYL ESTER
445, d1mkdG_, 0.9111, 2.10, 0.244, 328, 307, CRYSTAL STRUCTURE OF PDE4D CATALYTIC DOMAIN AND ZARDAVERINE COMPLEX
446, d1mkdB_, 0.9111, 2.10, 0.244, 328, 307, CRYSTAL STRUCTURE OF PDE4D CATALYTIC DOMAIN AND ZARDAVERINE COMPLEX
447, d5k1iD_, 0.9108, 1.97, 0.252, 324, 305, PDE4 CRYSTAL STRUCTURE IN COMPLEX WITH SMALL MOLECULE INHIBITOR
448, d1xonB_, 0.9108, 1.91, 0.246, 322, 305, CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 4D IN COMPLEX WITH PICLAMILAST
449, d1tb7A_, 0.9108, 1.95, 0.245, 325, 306, CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 4D IN COMPLEX WITH AMP
450, p6f6uB_, 0.9107, 1.90, 0.246, 322, 305, CRYSTAL STRUCTURE OF THE PDE4D CATALYTIC DOMAIN IN COMPLEX WITH GEBR- 7B 
451, d1ro9B_, 0.9106, 2.10, 0.244, 328, 307, CRYSTAL STRUCTURES OF THE CATALYTIC DOMAIN OF PHOSPHODIESTERASE 4B2B COMPLEXED WITH 8-BR-AMP
452, d1mkdK_, 0.9106, 2.10, 0.244, 328, 307, CRYSTAL STRUCTURE OF PDE4D CATALYTIC DOMAIN AND ZARDAVERINE COMPLEX
453, d1mkdJ_, 0.9106, 1.91, 0.246, 326, 305, CRYSTAL STRUCTURE OF PDE4D CATALYTIC DOMAIN AND ZARDAVERINE COMPLEX
454, d1mkdE_, 0.9106, 1.90, 0.246, 326, 305, CRYSTAL STRUCTURE OF PDE4D CATALYTIC DOMAIN AND ZARDAVERINE COMPLEX
455, d1mkdD_, 0.9106, 1.90, 0.246, 321, 305, CRYSTAL STRUCTURE OF PDE4D CATALYTIC DOMAIN AND ZARDAVERINE COMPLEX
456, p6f8vB_, 0.9105, 1.97, 0.249, 324, 305, CRYSTAL STRUCTURE OF THE PDE4D CATALYTIC DOMAIN IN COMPLEX WITH GEBR- 18B 
457, p6f8uB_, 0.9105, 2.41, 0.240, 337, 313, CRYSTAL STRUCTURE OF THE PDE4D CATALYTIC DOMAIN IN COMPLEX WITH GEBR- 20B 
458, p6f8rB_, 0.9105, 1.98, 0.245, 328, 306, CRYSTAL STRUCTURE OF THE PDE4D CATALYTIC DOMAIN IN COMPLEX WITH GEBR- 54 
459, d1y2kB_, 0.9105, 1.98, 0.245, 328, 306, CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 4D IN COMPLEX WITH 35- DIMETHYL-1-(3-NITRO-PHENYL)-1H-PYRAZOLE-4-CARBOXYLIC ACID ETHYL ESTER
460, d1y2dB_, 0.9105, 1.98, 0.245, 328, 306, CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 4D IN COMPLEX WITH 1-(4- METHOXY-PHENYL)-35-DIMETHYL-1H-PYRAZOLE-4-CARBOXYLIC ACID ETHYL ESTER
461, d1tbbA_, 0.9105, 1.98, 0.245, 328, 306, CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 4D IN COMPLEX WITH ROLIPRAM
462, d1ptwB_, 0.9105, 1.96, 0.249, 324, 305, THE CRYSTAL STRUCTURE OF AMP-BOUND PDE4 SUGGESTS A MECHANISM FOR PHOSPHODIESTERASE CATALYSIS
463, d1mkdL_, 0.9105, 1.97, 0.249, 325, 305, CRYSTAL STRUCTURE OF PDE4D CATALYTIC DOMAIN AND ZARDAVERINE COMPLEX
464, d1mkdI_, 0.9105, 1.96, 0.249, 324, 305, CRYSTAL STRUCTURE OF PDE4D CATALYTIC DOMAIN AND ZARDAVERINE COMPLEX
465, d1mkdC_, 0.9105, 1.91, 0.246, 322, 305, CRYSTAL STRUCTURE OF PDE4D CATALYTIC DOMAIN AND ZARDAVERINE COMPLEX
466, p5g5vA_, 0.9104, 1.90, 0.246, 326, 305, CRYSTAL STRUCTURE OF T. BRUCEI PDE-B1 CATALYTIC DOMAIN WITH INHIBITOR NPD-038
467, d3v9bD_, 0.9104, 1.90, 0.246, 321, 305, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF PDE4D2 WITH (S)-N-(3-{1- [1-(3-CYCLOPROPYLMETHOXY-4-DIFLUOROMETHOXYPHENYL)-2-(1-OXYPYRIDIN-4- YL)-ETHYL]-1H-PYRAZL-3-YL}PHENYL)ACETAMIDE
468, p3g4gB_, 0.9104, 2.00, 0.242, 327, 306, CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 4D WITH REGULATORY DOMAIN AND D155871
469, d1y2eB_, 0.9104, 1.98, 0.245, 328, 306, CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 4D IN COMPLEX WITH 1-(4- AMINO-PHENYL)-35-DIMETHYL-1H-PYRAZOLE-4-CARBOXYLIC ACID ETHYL ESTER
470, d1xoqB_, 0.9104, 1.98, 0.245, 328, 306, CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 4D IN COMPLEX WITH ROFLUMILAST
471, d1mkdF_, 0.9104, 1.98, 0.245, 328, 306, CRYSTAL STRUCTURE OF PDE4D CATALYTIC DOMAIN AND ZARDAVERINE COMPLEX
472, d3sl4B_, 0.9103, 2.06, 0.277, 335, 310, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF PDE4D2 WITH COMPOUND 10D
473, d1xorA_, 0.9103, 2.09, 0.244, 326, 307, CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 4D IN COMPLEX WITH ZARDAVERINE
474, d1oymA_, 0.9103, 1.93, 0.252, 336, 305,  
475, d3v9bC_, 0.9102, 1.90, 0.246, 320, 305, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF PDE4D2 WITH (S)-N-(3-{1- [1-(3-CYCLOPROPYLMETHOXY-4-DIFLUOROMETHOXYPHENYL)-2-(1-OXYPYRIDIN-4- YL)-ETHYL]-1H-PYRAZL-3-YL}PHENYL)ACETAMIDE
476, d3sl5B_, 0.9102, 1.91, 0.246, 322, 305, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF PDE4D2 COMPLEXED WITH COMPOUND 10D
477, d2fm0A_, 0.9102, 1.98, 0.245, 328, 306, CRYSTAL STRUCTURE OF PDE4D IN COMPLEX WITH L-869298
478, d1xonA_, 0.9102, 1.96, 0.245, 325, 306, CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 4D IN COMPLEX WITH PICLAMILAST
479, d1xomB_, 0.9102, 1.91, 0.246, 321, 305, CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 4D IN COMPLEX WITH CILOMILAST
480, d1q9mA_, 0.9102, 2.10, 0.244, 334, 308, THREE DIMENSIONAL STRUCTURES OF PDE4D IN COMPLEX WITH ROLIPRAMS AND IMPLICATION ON INHIBITOR SELECTIVITY
481, d1rkoA_, 0.9101, 1.98, 0.245, 325, 306,  
482, d5h2rB_, 0.9100, 1.97, 0.245, 325, 306, CRYSTAL STRUCTURE OF T BRUCEI PHOSPHODIESTERASE B2 BOUND TO COMPOUND 15B
483, d3v93G_, 0.9100, 2.09, 0.244, 334, 308, UNLIGANDED STRUCTURE OF TCRPDEC1 CATALYTIC DOMAIN
484, d4phlA_, 0.9099, 1.92, 0.246, 322, 305, TBRPDEB1-INHIBITOR COMPLEX
485, p5lboB_, 0.9098, 1.92, 0.246, 321, 305, CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 4D2 CATALYTIC DOMAIN WITH INHIBITOR NPD-001
486, d2fm5A_, 0.9098, 2.10, 0.244, 334, 308, CRYSTAL STRUCTURE OF PDE4D2 IN COMPLEX WITH INHIBITOR L- 869299
487, d3g58A_, 0.9097, 2.10, 0.244, 334, 308, CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 4D WITH D155988/PMNPQ
488, d5k1iE_, 0.9096, 1.88, 0.296, 328, 307, PDE4 CRYSTAL STRUCTURE IN COMPLEX WITH SMALL MOLECULE INHIBITOR
489, d3sl6B_, 0.9096, 2.11, 0.197, 334, 309, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF PDE4D2 WITH COMPOUND 12C
490, d3iadB_, 0.9096, 2.03, 0.282, 330, 309, CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 4D WITH BOUND ALLOSTERIC MODULATOR
491, d2pw3B_, 0.9095, 1.97, 0.245, 324, 306, STRUCTURE OF THE PDE4D-CAMP COMPLEX
492, d5k1iH_, 0.9094, 2.09, 0.244, 334, 308, PDE4 CRYSTAL STRUCTURE IN COMPLEX WITH SMALL MOLECULE INHIBITOR
493, d5g57B_, 0.9094, 2.27, 0.246, 335, 309, CRYSTAL STRUCTURE OF T. BRUCEI PDE-B1 CATALYTIC DOMAIN WITH INHIBITOR NPD-001
494, d5g2bB_, 0.9094, 1.92, 0.246, 321, 305, CRYSTAL STRUCTURE OF T. BRUCEI PDE-B1 CATALYTIC DOMAIN WITH INHIBITOR NPD-008
495, p6f8wA_, 0.9093, 1.97, 0.245, 325, 306, CRYSTAL STRUCTURE OF THE PDE4D CATALYTIC DOMAIN IN COMPLEX WITH GEBR- 18A 
496, d5k1iF_, 0.9093, 1.97, 0.245, 338, 306, PDE4 CRYSTAL STRUCTURE IN COMPLEX WITH SMALL MOLECULE INHIBITOR
497, p5tkbA_, 0.9092, 1.97, 0.242, 325, 306, CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 4D IN COMPLEX WITH A TETRAFLUORANLINE COMPOUND
498, d5h2qB_, 0.9091, 1.92, 0.246, 326, 305, CRYSTAL STRUCTURE OF T BRUCEI PHOSPHODIESTERASE B2 BOUND TO COMPOUND 13E
499, d4kp6A_, 0.9091, 2.08, 0.277, 332, 310, CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 4B (PDE4B) IN COMPLEX WITH A [135]TRIAZINE DERIVATIVE
500, d1q9mB_, 0.9091, 2.07, 0.277, 332, 310, THREE DIMENSIONAL STRUCTURES OF PDE4D IN COMPLEX WITH ROLIPRAMS AND IMPLICATION ON INHIBITOR SELECTIVITY
501, p5lboA_, 0.9090, 1.79, 0.251, 322, 303, CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 4D2 CATALYTIC DOMAIN WITH INHIBITOR NPD-001
502, d5k1iB_, 0.9090, 1.90, 0.246, 326, 305, PDE4 CRYSTAL STRUCTURE IN COMPLEX WITH SMALL MOLECULE INHIBITOR
503, d3v93F_, 0.9090, 2.18, 0.244, 326, 308, UNLIGANDED STRUCTURE OF TCRPDEC1 CATALYTIC DOMAIN
504, d3sl4A_, 0.9090, 1.89, 0.296, 328, 307, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF PDE4D2 WITH COMPOUND 10D
505, d3ly2C_, 0.9090, 1.95, 0.246, 324, 305, CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 4B IN COMPLEX WITH A COUMARIN-BASED INHIBITOR
506, d5k1iC_, 0.9089, 2.12, 0.241, 327, 307, PDE4 CRYSTAL STRUCTURE IN COMPLEX WITH SMALL MOLECULE INHIBITOR
507, d3ly2G_, 0.9089, 2.12, 0.244, 330, 307, CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 4B IN COMPLEX WITH A COUMARIN-BASED INHIBITOR
508, d3g4lB_, 0.9089, 1.93, 0.246, 326, 305, CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 4D WITH ROFLUMILAST
509, d3ly2H_, 0.9088, 2.12, 0.197, 334, 309, CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 4B IN COMPLEX WITH A COUMARIN-BASED INHIBITOR
510, d1oynB_, 0.9088, 2.12, 0.197, 334, 309, CRYSTAL STRUCTURE OF PDE4D2 IN COMPLEX WITH (RS)-ROLIPRAM
511, d3sl8B_, 0.9084, 2.01, 0.245, 329, 306, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF PDE4D2 WITH COMPOUND 10O
512, d3g4iA_, 0.9084, 2.35, 0.241, 332, 311, CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 4D WITH D155871
513, d1tb5A_, 0.9084, 1.94, 0.246, 321, 305, CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 4B IN COMPLEX WITH AMP
514, d1oymB_, 0.9084, 2.31, 0.241, 332, 311,  
515, p5tkbD_, 0.9083, 2.00, 0.245, 326, 306, CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 4D IN COMPLEX WITH A TETRAFLUORANLINE COMPOUND
516, d1xmuA_, 0.9083, 2.31, 0.241, 332, 311, CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 4B IN COMPLEX WITH ROFLUMILAST
517, d1f0jB_, 0.9083, 2.01, 0.245, 327, 306, CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 4B2B
518, d1ptwC_, 0.9082, 2.08, 0.252, 324, 306, THE CRYSTAL STRUCTURE OF AMP-BOUND PDE4 SUGGESTS A MECHANISM FOR PHOSPHODIESTERASE CATALYSIS
519, d3g58B_, 0.9080, 2.08, 0.244, 331, 307, CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 4D WITH D155988/PMNPQ
520, d3g4iB_, 0.9080, 1.96, 0.246, 323, 305, CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 4D WITH D155871
521, d3g4lA_, 0.9078, 2.01, 0.242, 327, 306, CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 4D WITH ROFLUMILAST
522, d3sl5D_, 0.9077, 1.99, 0.245, 325, 306, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF PDE4D2 COMPLEXED WITH COMPOUND 10D
523, d3g4kB_, 0.9076, 2.15, 0.247, 329, 308, CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 4D WITH ROLIPRAM
524, d1oynC_, 0.9076, 2.33, 0.240, 337, 312, CRYSTAL STRUCTURE OF PDE4D2 IN COMPLEX WITH (RS)-ROLIPRAM
525, p6f8xA_, 0.9075, 2.05, 0.245, 327, 306, CRYSTAL STRUCTURE OF THE PDE4D CATALYTIC DOMAIN IN COMPLEX WITH GEBR- 26G 
526, p5tkbC_, 0.9075, 2.11, 0.244, 327, 307, CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 4D IN COMPLEX WITH A TETRAFLUORANLINE COMPOUND
527, p5lboD_, 0.9075, 2.00, 0.245, 326, 306, CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 4D2 CATALYTIC DOMAIN WITH INHIBITOR NPD-001
528, p5lboC_, 0.9075, 2.05, 0.245, 327, 306, CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 4D2 CATALYTIC DOMAIN WITH INHIBITOR NPD-001
529, d3v93C_, 0.9075, 1.94, 0.246, 324, 305, UNLIGANDED STRUCTURE OF TCRPDEC1 CATALYTIC DOMAIN
530, d3sl5A_, 0.9075, 2.00, 0.245, 326, 306, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF PDE4D2 COMPLEXED WITH COMPOUND 10D
531, p6f8rA_, 0.9074, 2.02, 0.245, 327, 306, CRYSTAL STRUCTURE OF THE PDE4D CATALYTIC DOMAIN IN COMPLEX WITH GEBR- 54 
532, d4w1oB_, 0.9074, 1.92, 0.250, 322, 304, PDE4D COMPLEXED WITH INHIBITOR
533, d1xotB_, 0.9074, 2.02, 0.245, 323, 306, CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 4B IN COMPLEX WITH VARDENAFIL
534, d3sl4D_, 0.9073, 1.95, 0.246, 324, 305, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF PDE4D2 WITH COMPOUND 10D
535, d3iadD_, 0.9073, 1.94, 0.246, 323, 305, CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 4D WITH BOUND ALLOSTERIC MODULATOR
536, d3g4iC_, 0.9073, 2.04, 0.198, 333, 308, CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 4D WITH D155871
537, d3sl8D_, 0.9071, 2.08, 0.245, 328, 306, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF PDE4D2 WITH COMPOUND 10O
538, d1zknB_, 0.9071, 1.94, 0.250, 322, 304, STRUCTURE OF PDE4D2-IBMX
539, d1tb5B_, 0.9071, 2.05, 0.245, 325, 306, CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 4B IN COMPLEX WITH AMP
540, d1sojL_, 0.9071, 2.00, 0.246, 322, 305, CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 3B IN COMPLEX WITH IBMX
541, d1sojJ_, 0.9071, 1.95, 0.246, 324, 305, CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 3B IN COMPLEX WITH IBMX
542, d1sojH_, 0.9071, 2.02, 0.245, 339, 306, CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 3B IN COMPLEX WITH IBMX
543, d1sojF_, 0.9071, 2.02, 0.245, 327, 306, CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 3B IN COMPLEX WITH IBMX
544, d1sojD_, 0.9071, 1.96, 0.246, 324, 305, CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 3B IN COMPLEX WITH IBMX
545, d1sojB_, 0.9071, 2.03, 0.245, 327, 306, CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 3B IN COMPLEX WITH IBMX
546, d1rkoB_, 0.9071, 1.97, 0.246, 323, 305,  
547, p6f8uA_, 0.9070, 1.83, 0.221, 381, 303, CRYSTAL STRUCTURE OF THE PDE4D CATALYTIC DOMAIN IN COMPLEX WITH GEBR- 20B 
548, p4ogbD_, 0.9070, 1.83, 0.221, 381, 303, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF PDE4D2 WITH COMPOUND 2
549, d3ly2E_, 0.9070, 1.83, 0.221, 381, 303, CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 4B IN COMPLEX WITH A COUMARIN-BASED INHIBITOR
550, d2fm0B_, 0.9070, 1.83, 0.221, 381, 303, CRYSTAL STRUCTURE OF PDE4D IN COMPLEX WITH L-869298
551, d3g4kA_, 0.9069, 1.83, 0.221, 381, 303, CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 4D WITH ROLIPRAM
552, d3sl3D_, 0.9068, 1.83, 0.221, 381, 303, CRYSTAL STRUCTURE OF THE APO FORM OF THE CATALYTIC DOMAIN OF PDE4D2
553, d3o0jA_, 0.9068, 1.83, 0.221, 381, 303, PDE4B IN COMPLEX WITH LIGAND AN2898
554, d3w5eB_, 0.9067, 2.03, 0.245, 327, 306, CRYSTAL STRUCTURE OF PHOSPHODIESTERASE 4B IN COMPLEX WITH COMPOUND 31E
555, d3ly2F_, 0.9067, 1.92, 0.250, 322, 304, CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 4B IN COMPLEX WITH A COUMARIN-BASED INHIBITOR
556, d1zknC_, 0.9067, 1.96, 0.246, 324, 305, STRUCTURE OF PDE4D2-IBMX
557, d1rkoC_, 0.9067, 2.21, 0.243, 329, 309,  
558, d3g4lC_, 0.9066, 2.14, 0.244, 327, 307, CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 4D WITH ROFLUMILAST
559, d2fm0C_, 0.9066, 2.04, 0.245, 330, 306, CRYSTAL STRUCTURE OF PDE4D IN COMPLEX WITH L-869298
560, d5k6jA_, 0.9065, 1.96, 0.246, 324, 305, HUMAN PHOSPODIESTERASE 4B IN COMPLEX WITH PYRIDYLOXY-BENZOXABOROLE BASED INHIBITOR
561, d3g4kC_, 0.9065, 1.92, 0.247, 323, 304, CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 4D WITH ROLIPRAM
562, d1q9mC_, 0.9065, 2.38, 0.241, 345, 311, THREE DIMENSIONAL STRUCTURES OF PDE4D IN COMPLEX WITH ROLIPRAMS AND IMPLICATION ON INHIBITOR SELECTIVITY
563, d3sl8A_, 0.9062, 2.20, 0.244, 329, 308, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF PDE4D2 WITH COMPOUND 10O
564, d3sl6A_, 0.9062, 2.03, 0.245, 330, 306, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF PDE4D2 WITH COMPOUND 12C
565, d1xotA_, 0.9062, 2.03, 0.245, 330, 306, CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 4B IN COMPLEX WITH VARDENAFIL
566, p4ogbA_, 0.9061, 1.97, 0.246, 326, 305, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF PDE4D2 WITH COMPOUND 2
567, d2fm5C_, 0.9061, 2.03, 0.242, 327, 306, CRYSTAL STRUCTURE OF PDE4D2 IN COMPLEX WITH INHIBITOR L- 869299
568, d2fm5B_, 0.9061, 1.93, 0.247, 323, 304, CRYSTAL STRUCTURE OF PDE4D2 IN COMPLEX WITH INHIBITOR L- 869299
569, d3wd9B_, 0.9060, 2.02, 0.245, 327, 306, CRYSTAL STRUCTURE OF PHOSPHODIESTERASE 4B IN COMPLEX WITH COMPOUND 10F
570, d3sl6D_, 0.9060, 2.04, 0.245, 329, 306, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF PDE4D2 WITH COMPOUND 12C
571, d4wcuD_, 0.9059, 2.00, 0.246, 327, 305, PDE4 COMPLEXED WITH INHIBITOR
572, d3wd9A_, 0.9059, 2.01, 0.246, 327, 305, CRYSTAL STRUCTURE OF PHOSPHODIESTERASE 4B IN COMPLEX WITH COMPOUND 10F
573, d3g58C_, 0.9059, 2.00, 0.246, 322, 305, CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 4D WITH D155988/PMNPQ
574, d2h44A_, 0.9059, 2.00, 0.246, 328, 305, CRYSTAL STRUCTURE OF PDE5A1 IN COMPLEX WITH ICARISID II
575, d1y2jA_, 0.9059, 2.04, 0.245, 327, 306, CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 4B IN COMPLEX WITH 35- DIMETHYL-1-(3-NITRO-PHENYL)-1H-PYRAZOLE-4-CARBOXYLIC ACID ETHYL ESTER
576, p4w1oA_, 0.9057, 2.16, 0.244, 327, 307, PDE4D COMPLEXED WITH INHIBITOR
577, d1sojC_, 0.9057, 2.40, 0.241, 345, 311, CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 3B IN COMPLEX WITH IBMX
578, d1sojK_, 0.9056, 1.98, 0.246, 324, 305, CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 3B IN COMPLEX WITH IBMX
579, d1sojI_, 0.9056, 1.95, 0.250, 330, 304, CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 3B IN COMPLEX WITH IBMX
580, d1sojA_, 0.9056, 2.29, 0.243, 345, 309, CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 3B IN COMPLEX WITH IBMX
581, p4w1oC_, 0.9055, 2.05, 0.242, 327, 306, PDE4D COMPLEXED WITH INHIBITOR
582, d1xlxA_, 0.9054, 1.83, 0.395, 326, 301, CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 4B IN COMPLEX WITH CILOMILAST
583, d1sojG_, 0.9054, 2.01, 0.246, 322, 305, CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 3B IN COMPLEX WITH IBMX
584, d1sojE_, 0.9054, 1.95, 0.250, 322, 304, CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 3B IN COMPLEX WITH IBMX
585, d1so2B_, 0.9053, 1.84, 0.221, 364, 303, CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 3B IN COMPLEX WITH A DIHYDROPYRIDAZINE INHIBITOR
586, d5k32B1, 0.9052, 1.84, 0.221, 364, 303, PDE4D CRYSTAL STRUCTURE IN COMPLEX WITH SMALL MOLECULE INHIBITOR
587, d1y2jB_, 0.9052, 1.84, 0.221, 364, 303, CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 4B IN COMPLEX WITH 35- DIMETHYL-1-(3-NITRO-PHENYL)-1H-PYRAZOLE-4-CARBOXYLIC ACID ETHYL ESTER
588, d3w5eA_, 0.9051, 1.84, 0.221, 364, 303, CRYSTAL STRUCTURE OF PHOSPHODIESTERASE 4B IN COMPLEX WITH COMPOUND 31E
589, d4wcuA_, 0.9050, 1.99, 0.246, 321, 305, PDE4 COMPLEXED WITH INHIBITOR
590, p4ogbB_, 0.9050, 2.03, 0.246, 322, 305, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF PDE4D2 WITH COMPOUND 2
591, d3v93B_, 0.9050, 1.84, 0.215, 364, 303, UNLIGANDED STRUCTURE OF TCRPDEC1 CATALYTIC DOMAIN
592, d3ly2D_, 0.9050, 1.84, 0.215, 364, 303, CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 4B IN COMPLEX WITH A COUMARIN-BASED INHIBITOR
593, d3sl4C_, 0.9049, 1.94, 0.224, 363, 304, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF PDE4D2 WITH COMPOUND 10D
594, d1y2hA_, 0.9049, 1.90, 0.241, 320, 303, CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 4B IN COMPLEX WITH 1-(2- CHLORO-PHENYL)-35-DIMETHYL-1H-PYRAZOLE-4-CARBOXYLIC ACID ETHYL ESTER
595, d5u7dB_, 0.9048, 2.02, 0.246, 322, 305, PDE2 CATALYTIC DOMAIN COMPLEXED WITH INHIBITORS
596, d1so2A_, 0.9048, 2.30, 0.243, 345, 309, CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 3B IN COMPLEX WITH A DIHYDROPYRIDAZINE INHIBITOR
597, d3iadC_, 0.9047, 1.96, 0.250, 330, 304, CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 4D WITH BOUND ALLOSTERIC MODULATOR
598, p5tkbB_, 0.9046, 1.85, 0.254, 321, 303, CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 4D IN COMPLEX WITH A TETRAFLUORANLINE COMPOUND
599, d3k4sA1, 0.9045, 2.08, 0.198, 333, 308, THE STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN PDE4D WITH 4- (3-BUTOXY-4-METHOXYPHENYL)METHYL-2-IMIDAZOLIDONE
600, d1xlxB_, 0.9045, 2.18, 0.244, 328, 307, CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 4B IN COMPLEX WITH CILOMILAST
601, d5k32A_, 0.9044, 1.95, 0.247, 325, 304, PDE4D CRYSTAL STRUCTURE IN COMPLEX WITH SMALL MOLECULE INHIBITOR
602, d1y2hB_, 0.9043, 2.03, 0.246, 322, 305, CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 4B IN COMPLEX WITH 1-(2- CHLORO-PHENYL)-35-DIMETHYL-1H-PYRAZOLE-4-CARBOXYLIC ACID ETHYL ESTER
603, d3sl6C_, 0.9042, 1.95, 0.349, 328, 304, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF PDE4D2 WITH COMPOUND 12C
604, d3v94E_, 0.9041, 2.10, 0.220, 363, 305, TCRPDEC1 CATALYTIC DOMAIN IN COMPLEX WITH INHIBITOR WYQ16
605, d1so2D_, 0.9041, 1.94, 0.247, 339, 304, CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 3B IN COMPLEX WITH A DIHYDROPYRIDAZINE INHIBITOR
606, d4wcuB_, 0.9039, 2.06, 0.246, 323, 305, PDE4 COMPLEXED WITH INHIBITOR
607, p4ogbC_, 0.9039, 2.11, 0.252, 327, 305, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF PDE4D2 WITH COMPOUND 2
608, d3sl3B_, 0.9039, 2.03, 0.246, 322, 305, CRYSTAL STRUCTURE OF THE APO FORM OF THE CATALYTIC DOMAIN OF PDE4D2
609, d5b25A_, 0.9036, 1.91, 0.241, 322, 303, CRYSTAL STRUCTURE OF HUMAN PDE1B WITH INHIBITOR 3
610, p4wziB2, 0.9036, 2.03, 0.246, 322, 305, CRYSTAL STRUCTURE OF CROSSLINK STABILIZED LONG-FORM PDE4B
611, d3sl3A_, 0.9035, 1.97, 0.247, 325, 304, CRYSTAL STRUCTURE OF THE APO FORM OF THE CATALYTIC DOMAIN OF PDE4D2
612, d3v94D_, 0.9032, 1.98, 0.199, 331, 306, TCRPDEC1 CATALYTIC DOMAIN IN COMPLEX WITH INHIBITOR WYQ16
613, p4wziA2, 0.9031, 1.86, 0.221, 365, 303, CRYSTAL STRUCTURE OF CROSSLINK STABILIZED LONG-FORM PDE4B
614, p4w1oD_, 0.9031, 2.05, 0.246, 333, 305, PDE4D COMPLEXED WITH INHIBITOR
615, d3v94C_, 0.9031, 1.96, 0.247, 325, 304, TCRPDEC1 CATALYTIC DOMAIN IN COMPLEX WITH INHIBITOR WYQ16
616, d3ecmA_, 0.9031, 1.80, 0.255, 320, 302, CRYSTAL STRUCTURE OF THE UNLIGANDED PDE8A CATALYTIC DOMAIN
617, d4wcuC_, 0.9030, 1.83, 0.238, 335, 303, PDE4 COMPLEXED WITH INHIBITOR
618, d3v93E_, 0.9030, 1.83, 0.238, 335, 303, UNLIGANDED STRUCTURE OF TCRPDEC1 CATALYTIC DOMAIN
619, d3sl5C_, 0.9030, 2.27, 0.247, 329, 308, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF PDE4D2 COMPLEXED WITH COMPOUND 10D
620, d3sl3C_, 0.9030, 2.13, 0.243, 327, 305, CRYSTAL STRUCTURE OF THE APO FORM OF THE CATALYTIC DOMAIN OF PDE4D2
621, d3ecnB_, 0.9029, 2.00, 0.199, 331, 306, CRYSTAL STRUCTURE OF PDE8A CATALYTIC DOMAIN IN COMPLEX WITH IBMX
622, d1xmyA_, 0.9029, 2.03, 0.249, 324, 305, CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 4B IN COMPLEX WITH (R)- ROLIPRAM
623, d3v94G_, 0.9028, 1.92, 0.251, 317, 303, TCRPDEC1 CATALYTIC DOMAIN IN COMPLEX WITH INHIBITOR WYQ16
624, d3iadA_, 0.9027, 2.00, 0.199, 333, 306, CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 4D WITH BOUND ALLOSTERIC MODULATOR
625, d3ecnA_, 0.9027, 2.12, 0.212, 338, 307, CRYSTAL STRUCTURE OF PDE8A CATALYTIC DOMAIN IN COMPLEX WITH IBMX
626, d3v94A_, 0.9026, 2.12, 0.212, 338, 307, TCRPDEC1 CATALYTIC DOMAIN IN COMPLEX WITH INHIBITOR WYQ16
627, d1xm4B_, 0.9026, 1.93, 0.254, 322, 303, CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 4B IN COMPLEX WITH PICLAMILAST
628, d1xm4A_, 0.9025, 1.89, 0.201, 329, 304, CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 4B IN COMPLEX WITH PICLAMILAST
629, d3v94F_, 0.9024, 1.98, 0.247, 325, 304, TCRPDEC1 CATALYTIC DOMAIN IN COMPLEX WITH INHIBITOR WYQ16
630, d5b25B_, 0.9021, 1.97, 0.247, 324, 304, CRYSTAL STRUCTURE OF HUMAN PDE1B WITH INHIBITOR 3
631, d1xmuB_, 0.9021, 2.11, 0.212, 338, 307, CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 4B IN COMPLEX WITH ROFLUMILAST
632, d1xlzA_, 0.9018, 2.01, 0.247, 321, 304, CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 4B IN COMPLEX WITH FILAMINAST
633, d1xlzB_, 0.9016, 2.01, 0.199, 334, 306, CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 4B IN COMPLEX WITH FILAMINAST
634, p4x0fB2, 0.9015, 2.02, 0.243, 340, 304, CRYSTAL STRUCTURE OF CROSSLINK STABILIZED LONG-FORM PDE4B IN COMPLEX WITH (R)-(-)-ROLIPRAM
635, d3iakA1, 0.9015, 2.13, 0.212, 338, 307, CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 4D (PDE4D) WITH PAPAVERINE.
636, d3v94B_, 0.9014, 2.01, 0.199, 332, 306, TCRPDEC1 CATALYTIC DOMAIN IN COMPLEX WITH INHIBITOR WYQ16
637, d1xmyB_, 0.9014, 2.02, 0.247, 321, 304, CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 4B IN COMPLEX WITH (R)- ROLIPRAM
638, d5b25D_, 0.9009, 2.02, 0.247, 321, 304, CRYSTAL STRUCTURE OF HUMAN PDE1B WITH INHIBITOR 3
639, d3v93A_, 0.9008, 2.01, 0.199, 334, 306, UNLIGANDED STRUCTURE OF TCRPDEC1 CATALYTIC DOMAIN
640, d3sl8C_, 0.9007, 1.86, 0.238, 332, 303, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF PDE4D2 WITH COMPOUND 10O
641, d5b25C_, 0.9004, 2.02, 0.247, 321, 304, CRYSTAL STRUCTURE OF HUMAN PDE1B WITH INHIBITOR 3
642, d1xosA_, 0.8999, 2.03, 0.247, 321, 304, CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 4B IN COMPLEX WITH SILDENAFIL
643, d3v93H_, 0.8997, 2.04, 0.247, 321, 304, UNLIGANDED STRUCTURE OF TCRPDEC1 CATALYTIC DOMAIN
644, d3v94H_, 0.8996, 2.07, 0.249, 326, 305, TCRPDEC1 CATALYTIC DOMAIN IN COMPLEX WITH INHIBITOR WYQ16
645, d1xn0A_, 0.8993, 1.94, 0.252, 324, 302, CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 4B IN COMPLEX WITH (RS)- ROLIPRAM
646, d5xkmF_, 0.8991, 2.03, 0.199, 334, 306, CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 2A IN COMPLEX WITH 6- METHYL-N-(1-(4-(TRIFLUOROMETHOXY)PHENYL)PROPYL)PYRAZOLO[15- A]PYRIMIDINE-3-CARBOXAMIDE
647, d1xn0B_, 0.8987, 2.04, 0.247, 321, 304, CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 4B IN COMPLEX WITH (RS)- ROLIPRAM
648, d1xm6B_, 0.8980, 1.88, 0.238, 332, 303, CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 4B IN COMPLEX WITH (R)- MESOPRAM
649, d1xm6A_, 0.8976, 1.93, 0.201, 329, 304, CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 4B IN COMPLEX WITH (R)- MESOPRAM
650, d5uoyA_, 0.8975, 1.97, 0.244, 324, 303, CRYSTAL STRUCTURE OF HUMAN PDE1B CATALYTIC DOMAIN IN COMPLEX WITH INHIBITOR 16J (6-(4-METHOXYBENZYL)-9-((TETRAHYDRO-2H-PYRAN-4-YL) METHYL)-891011-TETRAHYDROPYRIDO[4 3 :45]THIENO[32-E][12 4]TRIAZOLO[15-C]PYRIMIDIN-5(6H)-ONE)
651, p5w6eA_, 0.8974, 1.87, 0.238, 332, 303, PDE1B COMPLEXED WITH COMPOUND 3S 
652, d5up0A_, 0.8974, 2.01, 0.248, 319, 303, CRYSTAL STRUCTURE OF HUMAN PDE1B CATALYTIC DOMAIN IN COMPLEX WITH INHIBITOR 3 (6-(4-CHLOROBENZYL)-891011-TETRAHYDROBENZO[4 5]THIENO[32-E][124]TRIAZOLO[15-C]PYRIMIDIN-5(6H)-ONE)
653, d4npwA_, 0.8974, 1.89, 0.201, 328, 303, CRYSTAL STRUCTURE OF HUMAN PDE1B BOUND TO INHIBITOR 19A (78- DIMETHOXY-N-[(2S)-1-(3-METHYL-1H-PYRAZOL-5-YL)PROPAN-2-YL]QUINAZOLIN- 4-AMINE)
654, d4npvA_, 0.8971, 2.00, 0.200, 330, 305, CRYSTAL STRUCTURE OF HUMAN PDE1B BOUND TO INHIBITOR 7A (678- TRIMETHOXY-N-(PENTAN-3-YL)QUINAZOLIN-4-AMINE)
655, d4llpB1, 0.8967, 2.03, 0.248, 320, 303, CRYSTAL STRUCTURE OF PDE10A2 WITH FRAGMENT ZT401
656, d3kktA_, 0.8950, 1.88, 0.346, 321, 301, CRYSTAL STRUCTURE OF HUMAN PDE4B WITH 5-[3-[(1S2S4R)- BICYCLO[2.2.1]HEPT-2-YLOXY]-4-METHOXYP HENYL]TETRAHYDRO-2(1H)- PYRIMIDINONE REVEALS ORDERING OF THE C-TERMINAL HELIX RESIDUES 502- 509.
657, d4y2bA_, 0.8929, 2.03, 0.248, 320, 303, CO-CRYSTAL STRUCTURE OF 3-ETHYL-2-(ISOPROPYLAMINO)-7-(PYRIDIN-3-YL) THIENO[32-D]PYRIMIDIN-4(3H)-ONE BOUND TO PDE7A
658, d3kktB_, 0.8927, 2.06, 0.248, 331, 303, CRYSTAL STRUCTURE OF HUMAN PDE4B WITH 5-[3-[(1S2S4R)- BICYCLO[2.2.1]HEPT-2-YLOXY]-4-METHOXYP HENYL]TETRAHYDRO-2(1H)- PYRIMIDINONE REVEALS ORDERING OF THE C-TERMINAL HELIX RESIDUES 502- 509.
659, d5xkmE_, 0.8925, 2.05, 0.248, 335, 303, CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 2A IN COMPLEX WITH 6- METHYL-N-(1-(4-(TRIFLUOROMETHOXY)PHENYL)PROPYL)PYRAZOLO[15- A]PYRIMIDINE-3-CARBOXAMIDE
660, d3g3nA_, 0.8921, 1.86, 0.243, 321, 301, PDE7A CATALYTIC DOMAIN IN COMPLEX WITH 3-(26- DIFLUOROPHENYL)-2-(METHYLTHIO)QUINAZOLIN-4(3H)-ONE
661, d3v93D_, 0.8903, 1.89, 0.242, 321, 302, UNLIGANDED STRUCTURE OF TCRPDEC1 CATALYTIC DOMAIN
662, p3jbqB_, 0.8900, 1.85, 0.243, 321, 301, DOMAIN ORGANIZATION AND CONFORMATIONAL PLASTICITY OF THE G PROTEIN EFFECTOR PDE6
663, p3jbqF_, 0.8896, 1.89, 0.242, 321, 302, DOMAIN ORGANIZATION AND CONFORMATIONAL PLASTICITY OF THE G PROTEIN EFFECTOR PDE6
664, d4pm0A_, 0.8893, 1.83, 0.243, 323, 301, PDE7A CATALYTIC DOMAIN IN COMPLEX WITH 2-(CYCLOPENTYLAMINO)THIENO[32- D]PYRIMIDIN-4(3H)-ONE DERIVATIVE
665, d1zklA_, 0.8892, 1.36, 1.000, 303, 292, MULTIPLE DETERMINANTS FOR INHIBITOR SELECTIVITY OF CYCLIC NUCLEOTIDE PHOSPHODIESTERASES
666, d5c29B_, 0.8890, 2.19, 0.236, 347, 305, PDE10 COMPLEXED WITH 6-CHLORO-2-CYCLOPROPYL-5-METHYL-N-PROPYL- PYRIMIDIN-4-AMINE
667, d3bjcA_, 0.8840, 1.98, 0.257, 318, 303, CRYSTAL STRUCTURE OF THE PDE5A CATALYTIC DOMAIN IN COMPLEX WITH A NOVEL INHIBITOR
668, d1rkpA_, 0.8828, 2.33, 0.239, 338, 305, CRYSTAL STRUCTURE OF PDE5A1-IBMX
669, d1tazA_, 0.8818, 1.89, 0.348, 319, 299, CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 1B
670, d3sieB_, 0.8797, 1.99, 0.261, 318, 303, CRYSTAL STRUCTURE OF THE PDE5A1 CATALYTIC DOMAIN IN COMPLEX WITH NOVEL INHIBITORS
671, d2h40A_, 0.8778, 1.99, 0.261, 318, 303, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF UNLIGANDED PDE5
672, d4dffB_, 0.8764, 1.94, 0.203, 324, 300, THE SAR DEVELOPMENT OF DIHYDROIMIDAZOISOQUINOLINE DERIVATIVES AS PHOSPHODIESTERASE 10A INHIBITORS FOR THE TREATMENT OF SCHIZOPHRENIA
673, d5vp0C_, 0.8760, 2.52, 0.417, 328, 314, DISCOVERY OF CLINICAL CANDIDATE N-{(1S)-1-[3-FLUORO-4- (TRIFLUOROMETHOXY)PHENYL]-2-METHOXYETHYL}-7-METHOXY-2-OXO-23- DIHYDROPYRIDO[23-B]PYRAZINE-4(1H)-CARBOXAMIDE (TAK-915) A HIGHLY POTENT SELECTIVE AND BRAIN-PENETRATING PHOSPHODIESTERASE 2A INHIBITOR FOR THE TREATMENT OF COGNITIVE DISORDERS
674, d3sieA_, 0.8741, 2.52, 0.417, 328, 314, CRYSTAL STRUCTURE OF THE PDE5A1 CATALYTIC DOMAIN IN COMPLEX WITH NOVEL INHIBITORS
675, d5u7lB_, 0.8707, 2.12, 0.247, 318, 304, PDE2 CATALYTIC DOMAIN COMPLEXED WITH INHIBITORS
676, d3shyA_, 0.8694, 2.11, 0.247, 317, 304, CRYSTAL STRUCTURE OF THE PDE5A1 CATALYTIC DOMAIN IN COMPLEX WITH NOVEL INHIBITORS
677, d4md6A_, 0.8665, 1.24, 0.997, 288, 288, CRYSTAL STRUCTURE OF PDE5 IN COMPLEX WITH INHIBITOR 5R
678, d3shzA_, 0.8661, 2.21, 0.378, 311, 299, CRYSTAL STRUCTURE OF THE PDE5A1 CATALYTIC DOMAIN IN COMPLEX WITH NOVEL INHIBITORS
679, d4i9zA_, 0.8634, 2.18, 0.378, 311, 299, CRYSTAL STRUCTURE OF THE PDE5A1 CATALYTIC DOMAIN IN COMPLEX WITH NOVEL INHIBITORS
680, p3ibjB3, 0.8601, 1.89, 0.236, 321, 297, X-RAY STRUCTURE OF PDE2A
681, d4oexA1, 0.8596, 1.74, 0.375, 300, 291, CRYSTAL STRUCTURE OF THE PDE5A1 CATALYTIC DOMAIN IN COMPLEX WITH NOVEL INHIBITORS
682, d4g2yA1, 0.8589, 2.25, 0.380, 311, 297, CRYSTAL STRUCTURE OF PDE5A COMPLEXED WITH ITS INHIBITOR
683, p3ibjA3, 0.8531, 0.37, 1.000, 277, 277, X-RAY STRUCTURE OF PDE2A
684, d4ia0A_, 0.8519, 1.82, 0.356, 311, 292, CRYSTAL STRUCTURE OF THE PDE5A1 CATALYTIC DOMAIN IN COMPLEX WITH NOVEL INHIBITORS
685, d4oewA_, 0.8469, 1.79, 0.376, 297, 290, CRYSTAL STRUCTURE OF THE PDE5A1 CATALYTIC DOMAIN IN COMPLEX WITH NOVEL INHIBITORS
686, d3b2rA2, 0.8461, 1.78, 0.352, 310, 290, CRYSTAL STRUCTURE OF PDE5A1 CATALYTIC DOMAIN IN COMPLEX WITH VARDENAFIL
687, d3itmB_, 0.8426, 1.81, 0.381, 298, 289, CATALYTIC DOMAIN OF HPDE2A
688, d3itmD_, 0.8425, 1.89, 0.381, 299, 289, CATALYTIC DOMAIN OF HPDE2A
689, d4g2wA_, 0.8420, 1.85, 0.378, 297, 288, CRYSTAL STRUCTURE OF PDE5A IN COMPLEX WITH ITS INHIBITOR
690, d3b2rB_, 0.8362, 1.74, 0.385, 296, 286, CRYSTAL STRUCTURE OF PDE5A1 CATALYTIC DOMAIN IN COMPLEX WITH VARDENAFIL
691, d3itmA_, 0.8336, 2.19, 0.326, 319, 291, CATALYTIC DOMAIN OF HPDE2A
692, d3itmC_, 0.8328, 1.86, 0.381, 296, 286, CATALYTIC DOMAIN OF HPDE2A
693, d1t9rA_, 0.8313, 1.91, 0.399, 296, 286, CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 5A
694, d2qymA_, 0.7812, 2.13, 0.333, 331, 288, CRYSTAL STRUCTURE OF UNLIGANDED PDE4C2
695, p6b96B1, 0.6595, 1.75, 0.387, 292, 282, CRYSTAL STRUCTURE OF PDE2 IN COMPLEX WITH COMPOUND 16
696, p6b96A1, 0.6586, 1.82, 0.388, 289, 281, CRYSTAL STRUCTURE OF PDE2 IN COMPLEX WITH COMPOUND 16
697, p6b98B1, 0.6583, 1.92, 0.379, 293, 282, PDE2 IN COMPLEX WITH COMPOUND 1
698, p6b97A1, 0.6572, 2.31, 0.324, 318, 287, CRYSTAL STRUCTURE OF PDE2 IN COMPLEX WITH COMPLEX 9
699, p5vydA1, 0.6325, 2.29, 0.328, 318, 287, CRYSTAL STRUCTURE OF PHOSPHODIESTERASE DOMAIN OF RHOPDE FUSION PROTEIN FROM THE CHOANOFLAGELLATE SALPINGOECA ROSETTA
700, p5vydB1, 0.6257, 1.65, 0.388, 286, 278, CRYSTAL STRUCTURE OF PHOSPHODIESTERASE DOMAIN OF RHOPDE FUSION PROTEIN FROM THE CHOANOFLAGELLATE SALPINGOECA ROSETTA
701, p6ezfA1, 0.6195, 1.98, 0.376, 287, 279, PDE2 IN COMPLEX WITH MOLECULE 5
702, p5vp1C1, 0.6029, 2.41, 0.323, 307, 285, DISCOVERY OF CLINICAL CANDIDATE N-{(1S)-1-[3-FLUORO-4- (TRIFLUOROMETHOXY)PHENYL]-2-METHOXYETHYL}-7-METHOXY-2-OXO-23- DIHYDROPYRIDO[23-B]PYRAZINE-4(1H)-CARBOXAMIDE (TAK-915) A HIGHLY POTENT SELECTIVE AND BRAIN-PENETRATING PHOSPHODIESTERASE 2A INHIBITOR FOR THE TREATMENT OF COGNITIVE DISORDERS
